<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2022.1026073</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>CircRNAs: Roles in regulating head and neck squamous cell carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Xiao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1971598"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tian</surname>
<given-names>Ruxian</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2092076"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Cai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2090656"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Yumei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1609553"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Song</surname>
<given-names>Xicheng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1019212"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Otorhinolaryngology Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai</institution>, <addr-line>Shandong</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai</institution>, <addr-line>Shandong</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>School of Clinical Medicine, Weifang Medical University, Weifang</institution>, <addr-line>Shandong</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Susanna Chiocca, European Institute of Oncology (IEO), Italy</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Zhaolei Cui, Fujian Medical University, China; Barbara Seliger, Martin Luther University of Halle-Wittenberg, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Xicheng Song, <email xlink:href="mailto:drxchsong@163.com">drxchsong@163.com</email>; Yumei Li, <email xlink:href="mailto:myheart1263@163.com">myheart1263@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>11</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>12</volume>
<elocation-id>1026073</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>08</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>10</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Han, Tian, Wang, Li and Song</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Han, Tian, Wang, Li and Song</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Head and neck squamous cell carcinoma (HNSCC), the most common head and neck malignant tumor, with only monotherapy, is characterized by poor prognosis, and low 5-year survival rate. Due to the lack of therapeutic targets, the targeted drugs for HNSCC are rare. Therefore, exploring the regulation mechanism of HNSCC and identifying effective therapeutic targets will be beneficial to its treatment of. Circular RNA (CircRNA) is a class of RNA molecules with a circular structure, which is widely expressed in human body. CircRNAs regulate gene expression by exerting the function as a miRNA sponge, thereby mediating the occurrence and development of HNSCC cell proliferation, apoptosis, migration, invasion, and other processes. In addition, circRNAs are also involved in the regulation of tumor sensitivity to chemical drugs and other biological functions. In this review, we systematically listed the functions of circRNAs and explored the regulatory mechanisms of circRNAs in HNSCC from the aspects of tumor growth, cell death, angiogenesis, tumor invasion and metastasis, tumor stem cell regulation, tumor drug resistance, immune escape, and tumor microenvironment. It will assist us in discovering new diagnostic markers and therapeutic targets, while encourage new ideas for the diagnosis and treatment of HNSCC.</p>
</abstract>
<kwd-group>
<kwd>head and neck squamous cell carcinoma</kwd>
<kwd>miRNA sponge function</kwd>
<kwd>tumor regulation</kwd>
<kwd>tumor microenvironment</kwd>
<kwd>circular RNAs</kwd>
</kwd-group>
<counts>
<fig-count count="2"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="187"/>
<page-count count="16"/>
<word-count count="5910"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Head and neck squamous cell carcinoma (HNSCC), originating from the mucosal epithelium of the mouth, pharynx, and larynx, is the sixth most common cancer worldwide (<xref ref-type="bibr" rid="B1">1</xref>). Approximately 42% of the patients with HNSCC are diagnosed as intermediate or advanced disease, and these patients often have local lymph node metastases (<xref ref-type="bibr" rid="B2">2</xref>). Moreover, HNSCC has a low response to treatment and high drug resistance, with a 5-year survival rate of only 40-50% and a poor prognosis (<xref ref-type="bibr" rid="B3">3</xref>). Therefore, the early diagnosis, intervention and seeking potential therapeutic targets for HNSCC are of great significance to improve the prognosis and survival quality of patients. In recent years, an increasing number of studies have been devoted to the identification of specific biomarkers for the clinical decision-making. Currently, some emerging biomarkers have encouraged new ideas for the clinical diagnosis and treatment of HNSCC, including some non-coding RNAs (ncRNAs), like long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), whose aberrant expression has been shown to be closely associated with the development of HNSCC (<xref ref-type="bibr" rid="B4">4</xref>). Particularly, circular RNAs (circRNAs), the newly discovered non-coding RNA molecules with closed-loop structure, have been proven to be a kind of new and stable biomarkers for diagnosis and treatment of HNSCC (<xref ref-type="bibr" rid="B5">5</xref>). CircRNAs exist widely in different species and cell lines, and are abundant, stable, conserved, and tissue-specific. In humans, they can be secreted into blood, saliva, and exosomes, playing an significant role in the tumor microenvironment. With the rapid development of next-generation sequencing technology, the basic structure and function of circRNAs have been fully confirmed, among which the functions ass HNSCC biomarkers and miRNA sponge, are extensively studied in recent years. However, the specific regulatory mechanism of circRNAs in the critical process of HNSCC development is still worth exploring. This review comprehensively described of the regulatory role of circRNAs in the development of HNSCC, interpreting the role and mechanism of circRNAs in the occurrence of this cancer, offering clues for diagnostic markers and therapeutic targets, and inspiring new ideas for the diagnosis and treatment of HNSCC.</p>
</sec>
<sec id="s2">
<title>CircRNAs</title>
<p>CircRNAs, first identified in viroids in 1976, are classified as non-coding RNA (<xref ref-type="bibr" rid="B6">6</xref>). They are characterized by extensive distribution, stability and high conservation (<xref ref-type="bibr" rid="B7">7</xref>). In humans, circRNAs can express in the vast majority of tissues (<xref ref-type="bibr" rid="B8">8</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>). However, different circRNAs express with tissue specificity or developmental stage specificity (<xref ref-type="bibr" rid="B13">13</xref>). Based on different splicing methods, circRNAs are divided into three main categories: exon circRNAs (ecircRNAs), exon-intron circRNAs (EIciRNAs), and intron circRNAs (ciRNAs). Many studies have focused on the most common circRNAs, namely ecircRNAs (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B14">14</xref>). According to recent research, the cyclization modes of circRNAs can be divided into intron cyclization and exon cyclization. There are several explanation models for the cyclization mechanism of circRNA: lariat-driven circularization (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B19">19</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>), intron reverse complementary sequence driven cyclization (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>), ciRNAs model (<xref ref-type="bibr" rid="B22">22</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>), and RNA binding protein driven cyclization (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>The biogenesis process and function of circRNA. <bold>(A)</bold> Lariat-driven circularization: During splicing of mRNA precursors, exon skipping produces a lariat intermediate containing both exons and introns. This intermediate will be reverse spliced and introns will be removed to form ecircRNAs. <bold>(B)</bold> Some introns on either side of one exon of a circRNA contain reverse complementary sequences. the RNA duplexes form two different types of circRNAs by variable splicing: circRNAs with introns and without introns, or introns within and on either side of one exon, which can compete for RNA pairing. <bold>(C)</bold> CiRNAs model. CiRNAs are generated by splicing reactions of introns. GU-rich elements near the 5&#x2019;-splice site and C-rich elements near the branching site stabilize CiRNAs to avoid splicing. <bold>(D)</bold> RNA-binding proteins (RBPs) drive the cyclization of circRNAs. RBPs facilitate the formation of circRNAs by bridging the two sides of introns together. <bold>(E)</bold> CircRNAs act as endogenous competitive RNAs or miRNA sponge in cytoplasm. <bold>(F)</bold> CircRNAs act as protein sponge or protein storage library. <bold>(G)</bold> CircRNAs regulate splicing. <bold>(H)</bold> CircRNAs regulate transcription. <bold>(I)</bold> Translation function of circRNA.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-g001.tif"/>
</fig>
<p>At present, the functions of circRNAs as endogenous competitive RNAs or miRNA sponge in cytoplasm are wide studied (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1E</bold>
</xref>). Competitive endogenous RNAs (ceRNAs) contain shared miRNA response elements (MRE), such as mRNAs, pseudogenes, and LncRNAs), enabling them to competitively bind miRNAs. CircRNAs with the same specific miRNA binding site may regulate the activity of competing endogenous RNA, thereby interfering the effect of miRNA on its target through competitive miRNA binding (<xref ref-type="bibr" rid="B14">14</xref>). Cerebellar degeneration&#x2010;related protein 1 antisense RNA (CDR1as), also known as circular RNA sponge for miR-7 (ciRS-7), was reported to antagonize miR-7 availability (<xref ref-type="bibr" rid="B25">25</xref>). By targeting different miRNAs and mRNAs, circRNAs are involved in the pathogenesis of a variety of diseases, including neurological diseases (<xref ref-type="bibr" rid="B26">26</xref>), psychiatric diseases (<xref ref-type="bibr" rid="B27">27</xref>), autoimmune diseases (<xref ref-type="bibr" rid="B28">28</xref>), cardiovascular diseases (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>), cartilage degenerative diseases (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B32">32</xref>), diabetes (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>), pulmonary fibrosis (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>), and various cancers (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B37">37</xref>&#x2013;<xref ref-type="bibr" rid="B39">39</xref>).</p>
<p>CircRNAs can also function as a protein sponge or protein storage library (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1F</bold>
</xref>). For example, circMBL can play a crucial role in balancing the expression levels of MBL mRNA and circMBL by isolating the excessive MBL protein (<xref ref-type="bibr" rid="B40">40</xref>).</p>
<p>CircRNAs regulate alternative splicing or transcription (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1G, H</bold>
</xref>). Back spliced of circRNAs may compete with linear spliced pre-mRNA for splicing sites. For example, the circMBL generated from the second exon of MBL has MBL binding sites flanking the intron (<xref ref-type="bibr" rid="B40">40</xref>). Thus, MBL level significantly affects circMBL biogenesis. Nuclear EIciRNAs with intronic sequences from parental genes, such as circEIF3J and circPAIP2, can interact with U1 small nuclear ribonucleotide proteins (snRNPs) and then bind to RNA polymerase II (Pol II) on the promoter of the parental gene, thereby enhancing gene expression (<xref ref-type="bibr" rid="B41">41</xref>). Besides, knocking down the expression of ElciRNAs has the potential to reduce the transcription of their parental genes (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>Since the ring structure of circRNA is formed by attaching its 3&#x2019;-end with 5&#x2019;-end through a unique back splicing, reducing essential translation elements such as 5&#x2019;-caps and poly-A tails, resulting in the blocked translation of most circRNAs. However, some circRNAs, such as circZNF609, circMb1, circ-FBXW7, circPINTexon2, and circ-SHPRH (<xref ref-type="bibr" rid="B42">42</xref>&#x2013;<xref ref-type="bibr" rid="B47">47</xref>), exerted their regulatory functions as polypeptides translated by ribosomes at internal ribosome entry sites (IRESs) or by incorporating with m6A ribonucleic acid in the untranslated region (UTR) on the 5&#x2019;-end (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B53">53</xref>), thus exerting their regulatory functions (<xref ref-type="bibr" rid="B22">22</xref>) (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1I</bold>
</xref>).</p>
<p>With the rapid development of bioinformatics, thousands of circRNAs in humans have been identified. CircRNAs have unique characteristics and a broad range of functions. As new important participant in the ncRNA network, circRNAs have been identified as key regulatory factors in various cancers. Based on existing knowledge of HNSCC characteristics, we assumed that circRNAs may play a possible role in various aspects of HNSCC.</p>
<sec id="s2_1">
<title>CircRNAs regulate tumor cell proliferation</title>
<p>Cancer cells can synthesize and respond to growth factors (GFs), which in turn promote their own proliferation, forming a positive feedback growth signaling circuit (<xref ref-type="bibr" rid="B54">54</xref>), that is, continuous proliferation signal stimulation and infinite division. This is the basis of tumorigenesis.</p>
<p>More than 90% of HNSCC patients were tested positive for epidermal growth factor receptor (EGFR) (<xref ref-type="bibr" rid="B55">55</xref>), which is highly expressed in a variety of solid tumors and triggers an intracellular growth factor transduction cascade to regulate cell growth (<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>). EGFR is overexpressed in HNSCC and can activate related pathways leading to the proliferation of cancer cells (<xref ref-type="bibr" rid="B58">58</xref>). Previous studies have confirmed that circRNAs can affect the proliferation of tumor cells by regulating the expression of EGFR in lung cancer (<xref ref-type="bibr" rid="B59">59</xref>), colorectal cancer (<xref ref-type="bibr" rid="B60">60</xref>), glioblastoma (<xref ref-type="bibr" rid="B61">61</xref>), melanoma (<xref ref-type="bibr" rid="B62">62</xref>) and other malignant tumors. In oral squamous cell carcinoma (OSCC), hsa_circ_0005379 is located in the upstream of EGFR. Overexpression of hsa_circ_0005379 expression can inhibit the expression levels of EGFR and phosphorylated EGFR, thus regulating the proliferation of OSCC tumor cells (<xref ref-type="bibr" rid="B63">63</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Overexpression of the circZNF609 can stimulate miRNA-134-5P, and then up-regulate EGFR to promote the proliferation of laryngeal squamous cell carcinoma (LSCC) cells and the progression of LSCC (<xref ref-type="bibr" rid="B64">64</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Mechanisms of action and biological functions of key circRNAs involved in HNSCC.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">CircRNAs</th>
<th valign="top" align="center">Chromosome</th>
<th valign="top" align="center">Gene symbol</th>
<th valign="top" align="center">Splicing type</th>
<th valign="top" align="center">Cancer type</th>
<th valign="top" align="center">Expression</th>
<th valign="top" align="center">Targets/effectors</th>
<th valign="top" align="center">Biological function</th>
<th valign="top" align="center">Potential function</th>
<th valign="top" align="center">Gene structure</th>
<th valign="top" align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">hsa_circ_0005379</td>
<td valign="top" align="left">chr10</td>
<td valign="top" align="left">GDI2</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">EGFR</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circZNF609</td>
<td valign="top" align="left">chr15</td>
<td valign="top" align="left">ZNF609</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miRNA-134-5P<break/>/EGFR</td>
<td valign="top" align="left">Promotes<break/>proliferation</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i001.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B178">178</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ-NOTCH1</td>
<td valign="top" align="left">chr9</td>
<td valign="top" align="left">NOTCH1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">NPC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-34c-5p<break/>/c-Myc</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i002.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B179">179</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circCAMSAP1</td>
<td valign="top" align="left">chr9</td>
<td valign="top" align="left">CAMSAP1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">NPC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">SERPINH1<break/>/c-Myc</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i003.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B180">180</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circUHRF1</td>
<td valign="top" align="left">chr19</td>
<td valign="top" align="left">UHRF1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-526b-5p<break/>/c-Myc</td>
<td valign="top" align="left">Promotes<break/>proliferation</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i004.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B181">181</xref>)</td>
</tr>
<tr>
<td valign="top" rowspan="2" align="left">circCDR1as</td>
<td valign="top" rowspan="2" align="left">chrX</td>
<td valign="top" rowspan="2" align="left">CDR1</td>
<td valign="top" rowspan="2" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-7</td>
<td valign="top" align="left">Promotes<break/>proliferation</td>
<td valign="top" align="left">Prognosis and<break/>biomarker</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i005.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B182">182</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-671-5p</td>
<td valign="top" align="left">Promoted<break/>autophagy</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B183">183</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circANTRL1</td>
<td valign="top" align="left">chr10</td>
<td valign="top" align="left">ANTRL1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">miR-23a-3p<break/>/PTEN</td>
<td valign="top" align="left">Induce cell<break/>cycle arrest</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i006.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B72">72</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">hsa_circ_0006232</td>
<td valign="top" align="left">chr6</td>
<td valign="top" align="left">TRERF1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">PTEN</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circMYLK</td>
<td valign="top" align="left">chr3</td>
<td valign="top" align="left">MYLK</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-195<break/>/cyclin D1</td>
<td valign="top" align="left">Promotes proliferation<break/>accelerates cell cycle<break/>transition</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i007.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B74">74</xref>, <xref ref-type="bibr" rid="B184">184</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ-CCND1</td>
<td valign="top" align="left">chr11</td>
<td valign="top" align="left">CCND1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-646/CCND1</td>
<td valign="top" align="left">Accelerates cell cycle<break/>transition</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ_0000745</td>
<td valign="top" align="left">chr17</td>
<td valign="top" align="left">SPECC1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-488/CCND1</td>
<td valign="top" align="left">Induced cell cycle<break/>arrest</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">has_circ_0055538</td>
<td valign="top" align="left">chr2</td>
<td valign="top" align="left">RMND5A</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">p53/Bcl-2<break/>/Caspase</td>
<td valign="top" align="left">Tumor<break/>suppressor</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B80">80</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ_0005320</td>
<td valign="top" align="left">chr17</td>
<td valign="top" align="left">SEPT9</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-486-3p<break/>/miR-637</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i008.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B81">81</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ_0000218</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-139-3p<break/>/Smad3 axis</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B83">83</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circPARD3</td>
<td valign="top" align="left">chr10</td>
<td valign="top" align="left">PARD3</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">PRKCI-Akt-<break/>mTOR</td>
<td valign="top" align="left">Inhibit<break/>autophagy</td>
<td valign="top" align="left">Therapeutic<break/>target and<break/>biomarker</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i009.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B93">93</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">hsa_circ_0001766</td>
<td valign="top" align="left">chr7</td>
<td valign="top" align="left">PDIA4</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-877-3p<break/>/VEGFA</td>
<td valign="top" align="left">Oncogenic<break/>functions</td>
<td valign="top" align="left">Biomarker</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circRPMS1</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">RPMS1</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">NPC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-203, miR-31,<break/>and miR-451</td>
<td valign="top" align="left">Promote EMT,<break/>Oncogenic functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B106">106</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circEPSTI1</td>
<td valign="top" align="left">chr13</td>
<td valign="top" align="left">EPSTI1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-942-5p</td>
<td valign="top" align="left">Promote EMT,<break/>Oncogenic functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i010.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B107">107</xref>, <xref ref-type="bibr" rid="B185">185</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circCORO1C</td>
<td valign="top" align="left">chr12</td>
<td valign="top" align="left">CORO1C</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">let-7c-5p</td>
<td valign="top" align="left">Oncogenic functions</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i011.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B108">108</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circCRIM1</td>
<td valign="top" align="left">chr2</td>
<td valign="top" align="left">CRIM1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">NPC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">Promoted metastasis<break/>and EMT</td>
<td valign="top" align="left">Prognosis</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i012.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B109">109</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ_0000140</td>
<td valign="top" align="left">chr1</td>
<td valign="top" align="left">KIAA0907</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">miR-31, LATS2</td>
<td valign="top" align="left">Tumor suppressor</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i013.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B110">110</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">hg19_circ_0005033</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">LSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-4521</td>
<td valign="top" align="left">Oncogenic functions</td>
<td valign="top" align="left">Therapeutic<break/>target and<break/>biomarker</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B119">119</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ_0109291</td>
<td valign="top" align="left">chr19</td>
<td valign="top" align="left">ZNF714</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">miR-188-3p</td>
<td valign="top" align="left">Promotes cisplatin<break/>resistance</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B176">176</xref>, <xref ref-type="bibr" rid="B177">177</xref>, <xref ref-type="bibr" rid="B186">186</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circGNG7</td>
<td valign="top" align="left">chr19</td>
<td valign="top" align="left">GNG7</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">HNSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">Ser78, Ser82</td>
<td valign="top" align="left">Tumor suppressor</td>
<td valign="top" align="left">Prognostic<break/>and therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B133">133</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circ-PKD2</td>
<td valign="top" align="left">chr4</td>
<td valign="top" align="left">PKD2</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">down</td>
<td valign="top" align="left">miR-646, Atg13</td>
<td valign="top" align="left">Increase cisplatin<break/>sensitivity</td>
<td valign="top" align="left">Prognosis</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B134">134</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circCUX1</td>
<td valign="top" align="left">chr7</td>
<td valign="top" align="left">CUX1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">HPSCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">caspase 1</td>
<td valign="top" align="left">Radiotherapy tolerance</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i014.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B135">135</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circBART2.2</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">NPC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">IRF3</td>
<td valign="top" align="left">Promotes immune<break/>escape</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">&#x2013;</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B187">187</xref>)</td>
</tr>
<tr>
<td valign="top" align="left">circFAT1</td>
<td valign="top" align="left">chr4</td>
<td valign="top" align="left">FAT1</td>
<td valign="top" align="left">EIciRNAs</td>
<td valign="top" align="left">SCC</td>
<td valign="top" align="left">up</td>
<td valign="top" align="left">STAT3</td>
<td valign="top" align="left">Immunosuppressive<break/>environment</td>
<td valign="top" align="left">Therapeutic<break/>target</td>
<td valign="top" align="center">
<inline-graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-i015.tif"/>
</td>
<td valign="top" align="center">(<xref ref-type="bibr" rid="B122">122</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>CircRNA, circular RNA; OSCC, oral squamous cell carcinoma; LSCC, laryngeal squamous cell carcinoma; NPC, nasopharyngeal cancers; HNSCC, head and neck squamous cell carcinoma; SCC, squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>The regulatory roles of circRNAs in the occurrence and development of HNSCC.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-12-1026073-g002.tif"/>
</fig>
<p>C-Myc, a proto-oncogene and is highly expressed as a biomarker in different types of cancer (<xref ref-type="bibr" rid="B65">65</xref>), is also an important regulator for tumor cell proliferation. It has been shown that the circRNA circ-NOTCH1 plays an important regulatory role in the cell proliferation process of nasopharyngeal carcinoma (NPC) by targeting the miR-34c-5p/c-Myc axis (<xref ref-type="bibr" rid="B66">66</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Alternatively, circCAMSAP1 facilitates the expression of SERPINH1, a molecular chaperone closely associated with tumor proliferation and metastasis, by improving its mRNA stability through the 3&#x2019;-untranslated region (3&#x2019;UTR). High-level expression of SERPINH1 can reduce the ubiquitination-mediated degradation rate of c-Myc, boosting cell proliferation and promotion of the occurrence of NPC (<xref ref-type="bibr" rid="B67">67</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Wei Zhao et&#xa0;al. suggested that circUHRF1 acts as a foam of mir-526b-5p in OSCC, thereby positively regulating c-Myc, promoting cell proliferation and tumorigenesis in OSCC (<xref ref-type="bibr" rid="B68">68</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Nevertheless, tumor cells can evade from the supervision of inhibitory growth signals by blocking the expression or activation of tumor suppressors. MiR-7 is a tumor suppressor that regulates a variety of biological processes. In LSCC, the expression of CDR1as is negatively correlated with that of miR-7. Induced overexpression of CDR1as can promot the proliferation of two LSCC cell lines (Hep2 and AMC-HN-8). These effects, however, can be eliminated by knocking down CDR1as or overexpressing miR-7. This suggests that CDR1as acts as the miR-7 sponges. Further <italic>in vivo</italic> experiments showed that overexpression of CDR1as can upregulat Cyclin E1 (CCNE1) and PIK3CD, the key targets of miR-7, in Hep2 and AMC-HN-8 cells, increasing tumor proliferation index and facilitating tumor growth (<xref ref-type="bibr" rid="B25">25</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
</sec>
<sec id="s2_2">
<title>CircRNAs regulate tumor cell cycle</title>
<p>Multiple anti-proliferative signals serve to maintain cellular quiescence in normal cells (<xref ref-type="bibr" rid="B54">54</xref>) by blocking cell proliferation in the manner of cell cycle arrest (<xref ref-type="bibr" rid="B69">69</xref>). Phosphatase and tensin homolog gene (PTEN), is a tumor suppressor that induce cell cycle arrest, mostly at G1phase in tumor cells (<xref ref-type="bibr" rid="B70">70</xref>). While the germline mutations in PTEN substantially increase the risk of cancer (<xref ref-type="bibr" rid="B71">71</xref>). CircANTRL1 may act as a sponge for miR-23a-3p to promote PTEN expression and induce cell cycle arrest, ultimately contributing to improvement of radiosensitivity in OSCC (<xref ref-type="bibr" rid="B72">72</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Research also showed that silencing hsa_circ_0006232 in LSCC can enhance the expression of PTEN in tumor tissues and affect the process of LSCC (<xref ref-type="bibr" rid="B73">73</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>In addition to regulation of anti-proliferative signals, circRNAs can regulate tumor growth by modulating cell cycle mediators. Cyclin D1, a cell cycle regulator protein encoded by CCND1, promotes the G1-S transition by activating cyclin dependent kinases 4 (CDK4) or cyclin dependent kinases 6 (CDK6). The expression level of circMYLK in LSCC carcinoma tissues was significantly higher than that in adjacent para-cancerous tissues, can increase the level of cell cycle protein D1 in Tu-177 cells (LSCC cell line) through miR-195/cyclin D1 axis, accelerate the G1-S transition of cells, and then promote the proliferation of tumor cells (<xref ref-type="bibr" rid="B74">74</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Yan et&#xa0;al. showed that circ-CCND1 can increase CCND1 levels and promote LSCC cancer cell proliferation by interacting with HuR and miR-646 (<xref ref-type="bibr" rid="B75">75</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Kuang et&#xa0;al. suggested that in OSCC, circ_0000745 promotes OSCC progression by acting as a miR-488 sponge and by interacting with HuR proteins to regulate the expression of CCND1 (<xref ref-type="bibr" rid="B76">76</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
</sec>
<sec id="s2_3">
<title>CircRNAs are involved in resistance to tumor cell death</title>
<p>Apart from cell proliferation rate, cell death rate also determines the number of cells (<xref ref-type="bibr" rid="B54">54</xref>). Apoptosis and autophagy are the main mechanisms leading to cell depletion, and cancer cells have the ability to resist these mechanisms (<xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>Tumor cells can develop resistance to apoptosis by several mechanisms. Mutations can result in the loss of pro-apoptotic regulators, most commonly in the p53 tumor suppressor gene (<xref ref-type="bibr" rid="B54">54</xref>). B-cell lymphoma 2 associated X-protein gene (Bax) is regulated by P53 gene and encodes B-cell lymphoma 2 (Bcl-2) homologous water-soluble protein BAX, which promotes cell apoptosis (<xref ref-type="bibr" rid="B77">77</xref>). Overexpression of Bax would antagonize the protective effect of Bcl-2 and lead to cell death. Bax can also regulate the expression of apoptotic protease activator 1 (Apaf-1) and affect the mitochondrial apoptosis pathway (<xref ref-type="bibr" rid="B78">78</xref>). Apaf-1 ultimately regulates the caspase-family related proteins such as caspase-3, the most important end cleaving enzyme in apoptosis (<xref ref-type="bibr" rid="B79">79</xref>). When hsa_circ_0055538 was overexpressed in OSCC cell lines SCC9 and CAL27 cells, the expression levels of p53, p21, Bax, Apaf-1, caspase-3, and cleaved caspase-3 are increased, while that of Bcl-2 is decreased. When hsa_circ_0055538 is adjusted downward, the opposite result as above is obtained, which suggests that hsa_circ_0055538 may regulate the apoptotic process of OSCC tumor cells through the p53 signaling pathway (<xref ref-type="bibr" rid="B80">80</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Circ_0005320 knockdown can reduce the expression level of Bcl-2 and increase the expression level of BAX by regulating mir-637/mir-486-3p, thus promoting the apoptosis of OSCC cells (<xref ref-type="bibr" rid="B81">81</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Overexpression of Smad3 can promote apoptosis of many human cancers (<xref ref-type="bibr" rid="B82">82</xref>). Circ_0000218 was highly expressed in LSCC cells, while miR-139-3p was less expressed in LSCC cells and negatively regulated by circ_0000218. Silencing of circ_0000218 has been shown to suppress LSCC cell viability and promote apoptosis by negatively regulating miR-139-3p expression levels, while the effects can be reversed by Smad family member 3 (Smad3) overexpression. Thus, circ_0000218 inhibition inhibits the growth of LSCC by targeting the miR-139-3p/Smad3 axis (<xref ref-type="bibr" rid="B83">83</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Autophagy is a lysosome-dependent cellular degradation program that maintains energy metabolic homeostasis by eliminating toxic and potentially compromised cellular components, providing a source of nutrition and energy for cell survival in a starved state (<xref ref-type="bibr" rid="B84">84</xref>). Higher bioenergetic and nutritional requirements of cancer cells than normal cells. In the advanced process of malignancy, they may enable themselves to survive under low nutrient and hypoxic conditions by inducing autophagy (<xref ref-type="bibr" rid="B85">85</xref>). The signaling pathways involved in autophagy, including mammalian target of rapamycin (mTOR), phosphatidylinositol-3 kinase (PI3K)-protein kinase B (AKT) and mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinase (ERK), and protein kinase C iota type 1 (PRKC1) have been well established (<xref ref-type="bibr" rid="B86">86</xref>&#x2013;<xref ref-type="bibr" rid="B88">88</xref>). Among them, PRKCI is a member of the kinase C protein family and is considered to be an important target for cancer therapy (<xref ref-type="bibr" rid="B89">89</xref>&#x2013;<xref ref-type="bibr" rid="B91">91</xref>). It has been shown that PRKCI inhibits autophagy and promotes LSCC cell proliferation, migration, invasion, and chemoresistance. Qu et&#xa0;al. found that a decreasing expression of PRKCI in the U2OS cells (LSCC cell line) can enhance autophagy while suppress cell phenotype (<xref ref-type="bibr" rid="B92">92</xref>). In contrast, circPARD3 was able to inhibit Akt and mTOR phosphorylation and suppress autophagy in LSCC cells by activating the PRKCI-Akt-mTOR pathway, promoting malignant progression and chemoresistance in LSCC cells (<xref ref-type="bibr" rid="B93">93</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In OSCC, circCDR1as was significantly increased in OSCC cancer tissues (<xref ref-type="bibr" rid="B94">94</xref>). Transcription factor EB (TFEB), a major regulator of lysosomal and autophagic function, is enhanced under hypoxic conditions, and it can coordinate autophagosomal degradation by driving autophagy and lysosomal gene expression (<xref ref-type="bibr" rid="B95">95</xref>). The expression level of lysosomal-associated membrane protein 2 (LAMP2) also steadily increases under hypoxic conditions. CircCDR1as can act as a sponge for miR-671-5p to promote autophagy in cells under hypoxic conditions, thereby inducing elevated levels of TFEB and LAMP2 and regulating lysosomal function. CircCDR1as also promotes hypoxia-induced AKT and inhibits mTOR activity, suggesting that AKT/mTOR pathway and lysosomal activity contribute to circCDR1as-induced activation of autophagy under hypoxic conditions in OSCC (<xref ref-type="bibr" rid="B96">96</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
</sec>
<sec id="s2_4">
<title>CircRNAs regulate persistent tumor angiogenesis</title>
<p>The growth of tumors is often accompanied by angiogenesis. Vascular endothelial growth factor-A (VEGFA; also known as VEGF) is one of the main factors driving the generation and expansion of tumor vascular beds (<xref ref-type="bibr" rid="B97">97</xref>). Carbonic anhydrase 9 (CAIX) is involved in cancer angiogenesis under hypoxia (<xref ref-type="bibr" rid="B98">98</xref>). Tumor cells produce carbon dioxide intracellularly, which enters the extracellular environment by diffusion, resulting in a lower extracellular pH. Extracellular carbon dioxide undergoes a reversible hydration reaction in the presence of CAIX to produce bicarbonate and release protons. Subsequently, bicarbonate is transported into the cell by the Bt transporter protein, which binds to intracellular protons to form H<sub>2</sub>O and CO<sub>2</sub>. To overcome the lack of nutrients in tumor cells undera hypoxic state, vascular endothelial growth factor A (VEGFA) promotes angiogenesis by participating in the activation of intracellular pathways associated with angiogenesis (<xref ref-type="bibr" rid="B99">99</xref>), and for tumor cells, angiogenesis is an important process that promotes their metastasis (<xref ref-type="bibr" rid="B100">100</xref>). A recent study showed that hsa_circ_0001766 is involved in the ceRNA machinery in OSCC and plays an important role in OSCC cell progression through the hsa_circ_0001766/miR-877-3p/VEGFA axis (<xref ref-type="bibr" rid="B101">101</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Activation of the janus kinase-2 (JAK2)/activator of transcription 3 (STAT3) pathway has been reported to play a key role in a variety of oncogenic processes, including angiogenesis. In OSCC, circ_0005320/miR-486-3p or circ_0005320/miR-637 axis can activate the JAK2/STAT3 pathway on OSCC cells and promote angiogenesis (<xref ref-type="bibr" rid="B81">81</xref>).</p>
</sec>
<sec id="s2_5">
<title>CircRNAs regulate tumor invasion and metastasis</title>
<p>It is reported that 90% of death in cancer patients are caused by metastases rather than the primary tumor (<xref ref-type="bibr" rid="B102">102</xref>). During the progression of most cancers, tumor cells can migrate from the primary site, forming new colonies at distant sites. Epithelial-mesenchymal transition (EMT) has been shown to be an essential process in carcinoma cell migration and tissue metastasis (<xref ref-type="bibr" rid="B103">103</xref>). EMT involves a process of cellular reprogramming that convert epithelial cells into a mesenchymal-like phenotype. And this process is characterized by the loss of epithelial surface markers such as E-cadherin and the acquisition of mesenchymal markers such as vimentin and N-cadherin (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B105">105</xref>). It has been demonstrated that circRPMS1 can act as a sponge for miR-203, miR-31, and miR-451 to promote the deletion of E-cadherin and the upregulation of N-cadherin and vimentin in the NPC cell line C666-1 cells, thereby regulating the EMT and invasiveness of NPC cells (<xref ref-type="bibr" rid="B106">106</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In OSCC, circEPSTI1 functions as a sponge for miR-942-5p to activate EMT, which in turn promotes migration and invasion of OSCC cells (<xref ref-type="bibr" rid="B107">107</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In addition, circCORO1C can bind to let-7c-5p and block it to reduce the level of Pre-B-cell leukemia homeobox transcription factor 3 (PBX3), thus promoting EMT and stimulating LSCC cell invasion and migration <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B108">108</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). CircCRIM1 is overexpressed in NPC cells and distantly metastasized NPC tissues, and it induces EMT during the progression of NPC. When circCRIM1 expression was knocked down in NPC cell lines S18 and HONE1, NPC cell morphology changed from a spindle or elongated mesenchymal morphology to an epithelial morphology. Meanwhile, the expression of the epithelial marker E-cadherin was significantly increased and the expression of the mesenchymal markers N-cadherin and Vimentin were decreased in NPC cells, suggesting that circCRIM1 has oncogenic potential and may be a marker for predicting NPC metastasis (<xref ref-type="bibr" rid="B109">109</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Circ_0000140 derived from exons 7-10 of the KIAA0907 gene is downregulated in OSCC tissues and negatively correlates with the prognosis of OSCC patients. Further studies have shown that circ_0000140 can bind to miR-31 and upregulate its target gene large tumor suppressor kinase 2 (LATS2), thereby affecting the EMT of OSCC cells (<xref ref-type="bibr" rid="B110">110</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Epithelial splicing regulatory protein 1 (ESRP1), also known as RNA-binding motif protein 35A (RBM35A), is a key component in the EMT process in malignant tumors (<xref ref-type="bibr" rid="B111">111</xref>&#x2013;<xref ref-type="bibr" rid="B114">114</xref>), and it has been shown to be one of the splicing factors associated with EMT in tumor metastasis (<xref ref-type="bibr" rid="B8">8</xref>). The circUHRF1/miR-526b-5p/c-Myc axis was found to promote ESRP1 transcript levels in OSCC, and ESRP1 was also identified to target the flanking introns of circUHRF1 and accelerate its cyclization, forming a circUHRF1/miR-526b-5p/c-Myc/TGF-&#x3b2;1/ESRP1 feedback loop in the EMT progression (<xref ref-type="bibr" rid="B68">68</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
</sec>
<sec id="s2_6">
<title>CircRNAs regulate the stemness of HNSCC</title>
<p>Cancer stem cells (CSCs) are a fraction of cancer cells that have the ability to renew and initiate themselves, and are responsible for the metastasis and spread of cancer cells in the body and the failure of treatment (<xref ref-type="bibr" rid="B115">115</xref>&#x2013;<xref ref-type="bibr" rid="B117">117</xref>). CircRNAs have been shown to regulate the activity of tumor stem cells. CD133<sup>+</sup> and CD44<sup>+</sup> CSCs, also known as TDP cells, isolated from LSCC cells and highly express the stem cell markers Sex determining Region Y (SOX2) and octamer-binding transcription factor 4 (OCT4), have enhanced proliferation, migration, and colony formation, and are more resistant to chemotherapy and radiotherapy (<xref ref-type="bibr" rid="B118">118</xref>). Compared with parental cells, RNA sequencing of TDP cells showed 3684 differentially expressed circRNAs (<italic>p</italic> &lt; 0.01, log2FC &gt; 1) (<xref ref-type="bibr" rid="B119">119</xref>). Among them, Hg19_circ _0005033 upregulated in TDP cells, and acted as a sponge for miR-4521 to upregulate the target STAT5A expression thus inducing stem cell-like cells (<xref ref-type="bibr" rid="B120">120</xref>). Therefore, Hg19_circ_0005033 may support the stem cell properties of CD133<sup>+</sup> CD44<sup>+</sup> laryngeal CSCs through miR4521/STAT5A axis, which needs to be verified by further studies. SOX2 has been shown to regulate self-renewal and tumorigenicity of stem cell-like cells in HNSCC (<xref ref-type="bibr" rid="B121">121</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In nude mouse models with HNSCC, circFat1 KD can significantly inhibit SOX2 + cells and tumor stemness (<xref ref-type="bibr" rid="B122">122</xref>).</p>
</sec>
<sec id="s2_7">
<title>CircRNAs regulate chemotherapy and radiation therapy resistance in tumors</title>
<p>For the treatment of locally advanced disease, radiation therapy is used as an adjunct to surgery or in conjunction with chemotherapy (<xref ref-type="bibr" rid="B2">2</xref>). However, acquired chemotherapy resistance is one of the main reasons for treatment failure in patients with advanced tumors (<xref ref-type="bibr" rid="B123">123</xref>). ATP-binding cassette B1 (ABCB1) is a multidrug resistance-associated protein that is highly expressed in resistant cell lines and can promote chemotherapy resistance by pumping intracellular drugs extracellularly (<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>). Therefore, inhibition of ABCB1 expression is an effective way to reduce tumor drug resistance (<xref ref-type="bibr" rid="B126">126</xref>). Circ_0109291 promotes cisplatin resistance in oral squamous carcinoma by regulating ABCB1 expression mainly through adsorption of miR-188-3p. This provides a theoretical basis for reducing the incidence of drug resistance in OSCC (<xref ref-type="bibr" rid="B127">127</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Heat shock protein 27 (HSP27, also known as HSPB1), is a member of the small heat shock protein superfamily with Phospho-HSP27 (Ser15), Phospho-HSP27 (Ser78), and Phospho-HSP27 (Ser82) receptor sites (<xref ref-type="bibr" rid="B128">128</xref>). The function of HSP27 is regulated by post-translational phosphorylation (<xref ref-type="bibr" rid="B129">129</xref>, <xref ref-type="bibr" rid="B130">130</xref>). HSP27 enhances multidrug resistance in tongue squamous cell carcinoma (SCCT) by activating NF-&#x3ba;B (<xref ref-type="bibr" rid="B131">131</xref>). In LSCC, HSP27 overexpression creates cellular resistance to various cellular agents, such as cisplatin and staurosporin, by inducing cell cycle arrest and remodeling actin polymerization associated with drug uptake, respectively (<xref ref-type="bibr" rid="B132">132</xref>). CircGNG7 can block the phosphorylation sites of Ser78 and Ser82 and inhibit the phosphorylation of HSP27 in HNSCC, thus inhibiting the phosphorylation of HSP27 in the malignant signaling cascade, which may therefore reduce the chemotherapeutic resistance of HNSCC (<xref ref-type="bibr" rid="B133">133</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). In addition, in OSCC, circ-PKD2 is a tumor suppressor gene that promotes autophagy related 13 (Atg13) expression by sponging miR-646, thereby accelerating cisplatin sensitivity (<xref ref-type="bibr" rid="B134">134</xref>) (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Radiotherapy tolerance is also an important prognostic predictor for patients with HNSCC (<xref ref-type="bibr" rid="B135">135</xref>). CircCUX1, upregulated in patients with radiation-resistant hypopharyngeal squamous cell carcinoma (HPSCC), predicts poor survival outcomes. CircCUX1 binds to caspase 1 (a member of the caspase aspartate-specific protease family, also known as interleukin-1 &#x3b2; invertase) (<xref ref-type="bibr" rid="B136">136</xref>) mRNA and inhibits its expression, thus modulating the inflammatory response of tumor cells to radiation therapy and thereby producing radiation therapy tolerance (<xref ref-type="bibr" rid="B135">135</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
</sec>
<sec id="s2_8">
<title>CircRNAs regulate immune escape</title>
<p>The programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) signaling pathway is an important mechanism mediating tumor immunosuppression (<xref ref-type="bibr" rid="B137">137</xref>, <xref ref-type="bibr" rid="B138">138</xref>). PD-L1 is often expressed on the surface of tumor cells and immunosuppressive cells, and interacts with PD-1 on T cells, thus preventing tumor antigen-specific T cells from activating and killing tumor cells and leading to tumor immune escape (<xref ref-type="bibr" rid="B139">139</xref>&#x2013;<xref ref-type="bibr" rid="B144">144</xref>). It has been shown that circBART2.2, which is highly expressed in NPC, can activate the transcription factors interferon regulatory Factor 3 (IRF3) and nuclear factor kappa-B (NF-&#x3ba;B) upon binding to the decapping enzyme region of retinoic acid inducible gene protein I (RIG-I), which promotes the transcription of PD-L1 and thus leads to tumor immune escape (<xref ref-type="bibr" rid="B122">122</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>Juan Sun et&#xa0;al. proposed the following hypothesis: hsa_circ_001859, hsa-circ_001373, and hsa_circ_002179 may regulate the expression of PD-L1 and immunosuppressive molecule IL-10 through the ceRNA network to affect the immune evasion of LSCC, and then affect the degree of malignancy of LSCC. This hypothesis is likely to represent an important mechanism of immune evasion in LSCC, however, this hypothesis needs to be tested by large-scale scientific studies in the future (<xref ref-type="bibr" rid="B145">145</xref>).</p>
</sec>
<sec id="s2_9">
<title>CircRNAs regulate tumor microenvironment</title>
<p>Since 1989, the association between cancer and the tumor microenvironment (TME) has received increasing attention with the &#x201c;seed and soil theory&#x201d; hypothesis proposed by Stephen Paget (<xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B147">147</xref>). Growing amount of evidences have confirmed that tumor cells must recruit and reprogram surrounding normal cells in order to promote tumor progression (<xref ref-type="bibr" rid="B148">148</xref>). TME is mainly composed mainly of stromal cells and extracellular matrix (ECM) components. Stromal cells include immune cells, cancer-associated fibroblasts (CAFs), endothelial cells, and pericytes.</p>
<p>ECM is a highly dynamic structural network consisting of many stromal components bearing continuous remodeling mediated by several stromal degrading enzymes during tumorigenesis and progression (<xref ref-type="bibr" rid="B149">149</xref>). The protease matrix metalloproteinases (MMP) family supports the tumor cell invasion toward the basement membrane and stroma, the penetration of blood vessels, and metastasis by interacting with macromolecules on the basement membrane to degrade and stimulate ECM remodeling (<xref ref-type="bibr" rid="B150">150</xref>). Silencing of circZNF609 inhibited the proliferation and invasiveness of LSCC cells, and significantly increased the expression of MMP-2 protein (<xref ref-type="bibr" rid="B64">64</xref>), which may affect the degradation and remodeling of ECM in LSCC (<xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>). Moreover, in other tumors, like gastric cancer cells, protein expression levels of VEGF and migration-associated proteins MMP-2 and MMP-9 were significantly reduced after knockdown of circ-0000096, suggesting that circ-0000096 may affect cell growth and migration by regulating stromal remodeling and angiogenesis (<xref ref-type="bibr" rid="B151">151</xref>), as well as the TME. CircLMNB1, which is highly expressed in colorectal cancer (CRC), can downregulate MMP-2 and MMP-9 expression and inhibit EMT when its expression is knocked down, thereby affecting tumor dissemination and invasion (<xref ref-type="bibr" rid="B152">152</xref>). Silencing circDENND4C under hypoxic conditions downregulates the protein expression levels of MMP-2 and MMP-9 (<xref ref-type="bibr" rid="B153">153</xref>). All these provide a basis for future studies on the changes of TME in HNSCC.</p>
<p>Growing evidence suggests that the innate immune cells (macrophages, neutrophils, dendritic cells, innate lymphocytes, myeloid suppressor cells, and NK cells) as well as adaptive immune cells (T cells and B cells) contribute to tumor progression when present in TME (<xref ref-type="bibr" rid="B154">154</xref>). HNSCC is well known for having an immunosuppressive TME with low number of tumour infiltrating lymphocytes (<xref ref-type="bibr" rid="B155">155</xref>). In particular, the infiltration of CD8<sup>+</sup> T cells into the TME was low. Increasing the expression of circFAT1 in HNSCC can significantly increase the infiltration of CD8<sup>+</sup> T cells into tumors, which is an important molecular mechanism mediating the immunosuppressive environment of HNSCC (<xref ref-type="bibr" rid="B122">122</xref>) (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref> and <xref ref-type="table" rid="T1"><bold>Table 1</bold></xref>).</p>
<p>CircRNAs can interact with stromal cells, fibroblasts, and endothelial immune-related molecules in the TME of a variety of tumors, as well as various immune cells such as macrophages (<xref ref-type="bibr" rid="B156">156</xref>). However, the key role of more circRNAs in the TME of HNSCC is a challenge to be faced in the future.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>There are growing evidences that circRNAs have great potential in the diagnosis, treatment and prognosis of HNSCC. It is worth mentioning that regulatory effects of circRNAs described in our review are not independent of each other, but is usually closely related to various biological behaviors of cancer cells. For example, circZDBF2 promotes malignant cell behavior in OSCC, including cell proliferation, invasion, migration, and EMT processes (<xref ref-type="bibr" rid="B157">157</xref>). Upregulation of circRNA_100290 expression promotes proliferation, migration and invasion of LSCC cells while inhibiting apoptosis (<xref ref-type="bibr" rid="B158">158</xref>).</p>
<p>Current studies mostly focus on the clarification of mechanism of circRNAs based on full transcription sequencing of cancer tissues and normal adjacent tissues, and lack of circRNA expression data at the single-cell level of HNSCC. And these studies may be crucial for our future insight into circRNA function and advance the development of new biomarkers. However, to date, only a small number of functional circRNAs identified in HNSCC. Most of these circRNAs regulate the progression of HNSCC through miRNA sponge function. In addition, circRNAs interact with functional proteins, some of which have protein-coding potential. For example, circGNG7 mentioned in this paper can bind to serine residues 78 and 82 of HSP27 to reduce carcinogenic signal transduction.</p>
<p>Recent studies have also shown that circRNAs can regulate immune metabolism of HNSCC, and circ_0008068 may affect glycolysis by targeting mir-153-3p/acylglycerol kinase (AGK) axis and facilitate the CD8<sup>+</sup> T cell response (<xref ref-type="bibr" rid="B159">159</xref>). It provides a better understanding of the interaction between HNSCC cellular immunity and metabolic rate, and we look forward to opening up new immune-related therapies for HNSCC. The potential network of circRNAs-RBPs and other functions of circRNAs in HNSCC have important research value and potential application value. It is expected that circRNAs can be used as important biomarker for clinical diagnosis and treatment of HNSCC.</p>
<p>Studies have shown that circRNA has great potential in diagnosing pathological types of lung cancer (<xref ref-type="bibr" rid="B160">160</xref>) and molecular subtypes of breast cancer (<xref ref-type="bibr" rid="B161">161</xref>). Moreover, hsa_circ_0000190 and 0001649 could be used as biomarkers to predict recurrence and treatment response in patients with OSCC (<xref ref-type="bibr" rid="B162">162</xref>). CircRNAs have the advantages of high abundance and good stability, and can be detected in body fluids and blood (<xref ref-type="bibr" rid="B163">163</xref>, <xref ref-type="bibr" rid="B164">164</xref>), so it can be used as ideal diagnostic and predictive biomarkers for HNSCC diagnosis. In addition, Zhuo et&#xa0;al. analyzed the diagnostic value of various RNAs in hepatocellular carcinoma and with result showing that circRNAs &gt; lncRNAs &gt; microRNAs (<xref ref-type="bibr" rid="B165">165</xref>).</p>
<p>CircRNAs have shown great potential as therapeutic molecular tools in many cancers such as HNSCC (<xref ref-type="bibr" rid="B110">110</xref>, <xref ref-type="bibr" rid="B166">166</xref>, <xref ref-type="bibr" rid="B167">167</xref>), breast cancer (<xref ref-type="bibr" rid="B168">168</xref>), hepatocellular carcinoma (<xref ref-type="bibr" rid="B169">169</xref>), papillary thyroid cancer (<xref ref-type="bibr" rid="B170">170</xref>) gastric cancer (<xref ref-type="bibr" rid="B171">171</xref>). Compared with existing linear miRNA antagonists, circRNAs are structurally more stable, more resistant to degradation by nucleases without chemical modification, and well tolerated <italic>in vivo</italic> (<xref ref-type="bibr" rid="B172">172</xref>). The knockdown of oncogenic circRNAs in preclinical animal models validated circRNAs RNAi effect on tumor treatment (<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B173">173</xref>, <xref ref-type="bibr" rid="B174">174</xref>). Some researchers have attempted to design and synthesize tumor suppressive circRNAs <italic>in vitro</italic> for delivery into disease models to explore the potential of circRNA-like drug development. In the treatment of heart disease (<xref ref-type="bibr" rid="B172">172</xref>) and gastric malignancies (<xref ref-type="bibr" rid="B175">175</xref>), engineered circRNAs were delivered to <italic>in-vivo</italic> and <italic>in-vitro</italic> disease models to reverse pathogenic mechanisms. CircRNAs will be better diagnosis and treatment targets for HNSCC patients, which will benefit for the translation of basic to clinical medicine.</p>
<p>In conclusion, although the technical challenges concerning circRNAs have not been fully overcome yet, with the development of biological methods, informatics techniques, and further research, we will gain more and more understanding of the physiological functions and roles of circRNAs. The new diagnostic and therapeutic strategies for HNSCC based on circRNAs will effectively serve for the clinical work in the future.</p>
</sec>
<sec id="s4" sec-type="author-contributions">
<title>Author contributions</title>
<p>XH and RT conceived the paper and drafted the manuscript. XH and CW drew the figures. XS and YL edited and finalized the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s5" sec-type="funding-information">
<title>Funding</title>
<p>This work was supported by Taishan Scholars Project (No. ts20190991).</p>
</sec>
<sec id="s6" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s7" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moskovitz</surname> <given-names>J</given-names>
</name>
<name>
<surname>Moy</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ferris</surname> <given-names>RL</given-names>
</name>
</person-group>. <article-title>Immunotherapy for head and neck squamous cell carcinoma</article-title>. <source>Curr Oncol Rep</source> (<year>2018</year>) <volume>20</volume>(<issue>2</issue>):<fpage>22</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s11912-018-0654-5</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marur</surname> <given-names>S</given-names>
</name>
<name>
<surname>Forastiere</surname> <given-names>AA</given-names>
</name>
</person-group>. <article-title>Head and neck squamous cell carcinoma: Update on epidemiology, diagnosis, and treatment</article-title>. <source>Mayo Clinic Proc</source> (<year>2016</year>) <volume>91</volume>(<issue>3</issue>):<page-range>386&#x2013;96</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.mayocp.2015.12.017</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canning</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Myint</surname> <given-names>M</given-names>
</name>
<name>
<surname>Groves</surname> <given-names>MW</given-names>
</name>
<name>
<surname>Byrd</surname> <given-names>JK</given-names>
</name>
<etal/>
</person-group>. <article-title>Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy</article-title>. <source>Front Cell Dev Biol</source> (<year>2019</year>) <volume>7</volume>:<elocation-id>52</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2019.00052</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arantes</surname> <given-names>L</given-names>
</name>
<name>
<surname>De Carvalho</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Melendez</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Lopes Carvalho</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Serum, plasma and saliva biomarkers for head and neck cancer</article-title>. <source>Expert Rev Mol Diagnost</source> (<year>2018</year>) <volume>18</volume>(<issue>1</issue>):<fpage>85</fpage>&#x2013;<lpage>112</lpage>. doi: <pub-id pub-id-type="doi">10.1080/14737159.2017.1404906</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tie</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>X</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Role and mechanism of action of circular RNA and laryngeal cancer</article-title>. <source>Pathol Res Pract</source> (<year>2021</year>) <volume>223</volume>:<fpage>153460</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.prp.2021.153460</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanger</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Klotz</surname> <given-names>G</given-names>
</name>
<name>
<surname>Riesner</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gross</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Kleinschmidt</surname> <given-names>AK</given-names>
</name>
</person-group>. <article-title>Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures</article-title>. <source>Proc Natl Acad Sci U States A</source> (<year>1976</year>) <volume>73</volume>(<issue>11</issue>):<page-range>3852&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.73.11.3852</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>LL</given-names>
</name>
</person-group>. <article-title>The biogenesis, functions, and challenges of circular RNAs</article-title>. <source>Mol Cell</source> (<year>2018</year>) <volume>71</volume>(<issue>3</issue>):<page-range>428&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.034</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Pillman</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Toubia</surname> <given-names>J</given-names>
</name>
<name>
<surname>Conn</surname> <given-names>VM</given-names>
</name>
<name>
<surname>Salmanidis</surname> <given-names>M</given-names>
</name>
<name>
<surname>Phillips</surname> <given-names>CA</given-names>
</name>
<etal/>
</person-group>. <article-title>The RNA binding protein quaking regulates formation of circRNAs</article-title>. <source>Cell</source> (<year>2015</year>) <volume>160</volume>(<issue>6</issue>):<page-range>1125&#x2013;34</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.02.014</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeck</surname> <given-names>WR</given-names>
</name>
<name>
<surname>Sorrentino</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Slevin</surname> <given-names>MK</given-names>
</name>
<name>
<surname>Burd</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNAs are abundant, conserved, and associated with ALU repeats</article-title>. <source>RNA (New York NY)</source> (<year>2013</year>) <volume>19</volume>(<issue>2</issue>):<page-range>141&#x2013;57</page-range>. doi: <pub-id pub-id-type="doi">10.1261/rna.035667.112</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Hsueh</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNAs and their roles in head and neck cancers</article-title>. <source>Mol Cancer</source> (<year>2019</year>) <volume>18</volume>(<issue>1</issue>):<fpage>44</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-019-1003-5</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rybak-Wolf</surname> <given-names>A</given-names>
</name>
<name>
<surname>Stottmeister</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gla&#x17e;ar</surname> <given-names>P</given-names>
</name>
<name>
<surname>Jens</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pino</surname> <given-names>N</given-names>
</name>
<name>
<surname>Giusti</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed</article-title>. <source>Mol Cell</source> (<year>2015</year>) <volume>58</volume>(<issue>5</issue>):<page-range>870&#x2013;85</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2015.03.027</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salzman</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>RE</given-names>
</name>
<name>
<surname>Olsen</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>PO</given-names>
</name>
</person-group>. <article-title>Cell-type specific features of circular RNA expression</article-title>. <source>PloS Genet</source> (<year>2013</year>) <volume>9</volume>(<issue>9</issue>):<elocation-id>e1003777</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1003777</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Memczak</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jens</surname> <given-names>M</given-names>
</name>
<name>
<surname>Elefsinioti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Torti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Krueger</surname> <given-names>J</given-names>
</name>
<name>
<surname>Rybak</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNAs are a large class of animal RNAs with regulatory potency</article-title>. <source>Nature</source> (<year>2013</year>) <volume>495</volume>(<issue>7441</issue>):<page-range>333&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature11928</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>I</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Chuang</surname> <given-names>TJ</given-names>
</name>
</person-group>. <article-title>Biogenesis, identification, and function of exonic circular RNAs</article-title>. <source>Wiley Interdiscip Rev RNA</source> (<year>2015</year>) <volume>6</volume>(<issue>5</issue>):<page-range>563&#x2013;79</page-range>. doi: <pub-id pub-id-type="doi">10.1002/wrna.1294</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The emerging role and clinical implication of human exonic circular RNA</article-title>. <source>RNA Biol</source> (<year>2017</year>) <volume>14</volume>(<issue>8</issue>):<page-range>1000&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1080/15476286.2016.1227904</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname> <given-names>S</given-names>
</name>
<name>
<surname>Greenman</surname> <given-names>C</given-names>
</name>
<name>
<surname>Cook</surname> <given-names>PR</given-names>
</name>
<name>
<surname>Papantonis</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Exon skipping is correlated with exon circularization</article-title>. <source>J Mol Biol</source> (<year>2015</year>) <volume>427</volume>(<issue>15</issue>):<page-range>2414&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jmb.2015.02.018</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilusz</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>A 360&#xb0; view of circular RNAs: From biogenesis to functions</article-title>. <source>Wiley Interdiscip Rev RNA</source> (<year>2018</year>) <volume>9</volume>(<issue>4</issue>):<elocation-id>e1478</elocation-id>. doi: <pub-id pub-id-type="doi">10.1002/wrna.1478</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeck</surname> <given-names>WR</given-names>
</name>
<name>
<surname>Sharpless</surname> <given-names>NE</given-names>
</name>
</person-group>. <article-title>Detecting and characterizing circular RNAs</article-title>. <source>Nat Biotechnol</source> (<year>2014</year>) <volume>32</volume>(<issue>5</issue>):<page-range>453&#x2013;61</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nbt.2890</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>PL</given-names>
</name>
<name>
<surname>Salzman</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Circular RNA biogenesis can proceed through an exon-containing lariat precursor</article-title>. <source>eLife</source> (<year>2015</year>) <volume>4</volume>:<elocation-id>e07540</elocation-id>. doi: <pub-id pub-id-type="doi">10.7554/eLife.07540</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capel</surname> <given-names>B</given-names>
</name>
<name>
<surname>Swain</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nicolis</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hacker</surname> <given-names>A</given-names>
</name>
<name>
<surname>Walter</surname> <given-names>M</given-names>
</name>
<name>
<surname>Koopman</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular transcripts of the testis-determining gene sry in adult mouse testis</article-title>. <source>Cell</source> (<year>1993</year>) <volume>73</volume>(<issue>5</issue>):<page-range>1019&#x2013;30</page-range>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(93)90279-Y</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>XO</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>HB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Complementary sequence-mediated exon circularization</article-title>. <source>Cell</source> (<year>2014</year>) <volume>159</volume>(<issue>1</issue>):<page-range>134&#x2013;47</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2014.09.001</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Circular RNAs: Promising biomarkers for human diseases</article-title>. <source>EBioMedicine</source> (<year>2018</year>) <volume>34</volume>:<page-range>267&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2018.07.036</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>LL</given-names>
</name>
</person-group>. <article-title>The biogenesis and emerging roles of circular RNAs</article-title>. <source>Nat Rev Mol Cell Biol</source> (<year>2016</year>) <volume>17</volume>(<issue>4</issue>):<page-range>205&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrm.2015.32</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shang</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA: A new star of noncoding RNAs</article-title>. <source>Cancer Lett</source> (<year>2015</year>) <volume>365</volume>(<issue>2</issue>):<page-range>141&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2015.06.003</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>CDR1as is overexpressed in laryngeal squamous cell carcinoma to promote the tumour's progression <italic>via</italic> miR-7 signals</article-title>. <source>Cell Prolif</source> (<year>2018</year>) <volume>51</volume>(<issue>6</issue>):<elocation-id>e12521</elocation-id>. doi: <pub-id pub-id-type="doi">10.1111/cpr.12521</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel insight into circular RNA HECTD1 in astrocyte activation <italic>via</italic> autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke</article-title>. <source>Autophagy</source> (<year>2018</year>) <volume>14</volume>(<issue>7</issue>):<page-range>1164&#x2013;84</page-range>. doi: <pub-id pub-id-type="doi">10.1080/15548627.2018.1458173</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Identification of functional CircRNA-miRNA-mRNA regulatory network in dorsolateral prefrontal cortex neurons of patients with cocaine use disorder</article-title>. <source>Front Mol Neurosci</source> (<year>2022</year>) <volume>15</volume>:<elocation-id>839233</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2022.839233</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>YQ</given-names>
</name>
<etal/>
</person-group>. <article-title>Triptolide inhibits cell growth and inflammatory response of fibroblast-like synoviocytes by modulating hsa-circ-0003353/microRNA-31-5p/CDK1 axis in rheumatoid arthritis</article-title>. <source>Int Immunopharmacol</source> (<year>2022</year>) <volume>106</volume>:<fpage>108616</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2022.108616</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation</article-title>. <source>J Clin Invest</source> (<year>2021</year>) <volume>131</volume>(<issue>24</issue>):<elocation-id>e147031</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/JCI147031</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction</article-title>. <source>Theranostics</source> (<year>2021</year>) <volume>11</volume>(<issue>13</issue>):<page-range>6315&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.7150/thno.52843</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Song</surname> <given-names>G</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Su</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YM</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Interactions among lncRNA/circRNA, miRNA, and mRNA in musculoskeletal degenerative diseases</article-title>. <source>Front Cell Dev Biol</source> (<year>2021</year>) <volume>9</volume>:<elocation-id>753931</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2021.753931</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>CircNFIX regulates chondrogenesis and cartilage homeostasis by targeting the miR758-3p/KDM6A axis</article-title>. <source>Cell Prolif</source> (<year>2022</year>) <volume>55</volume>(<issue>11</issue>):<elocation-id>e13302</elocation-id>. doi: <pub-id pub-id-type="doi">10.1111/cpr.13302</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Analysis of circRNA-mRNA expression profiles and functional enrichment in diabetes mellitus based on high throughput sequencing</article-title>. <source>Int Wound J</source> (<year>2022</year>) <volume>19</volume>(<issue>5</issue>):<page-range>1253&#x2013;62</page-range>. doi: <pub-id pub-id-type="doi">10.1111/iwj.13838</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>circMAP3K4 regulates insulin resistance in trophoblast cells during gestational diabetes mellitus by modulating the miR-6795-5p/PTPN1 axis</article-title>. <source>J Trans Med</source> (<year>2022</year>) <volume>20</volume>(<issue>1</issue>):<fpage>180</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-022-03386-8</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Peripheral blood circular RNA hsa_circ_0058493 as a potential novel biomarker for silicosis and idiopathic pulmonary fibrosis</article-title>. <source>Ecotoxicol Environ Safety</source> (<year>2022</year>) <volume>236</volume>:<fpage>113451</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ecoenv.2022.113451</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The combined effects of circular RNA methylation promote pulmonary fibrosis</article-title>. <source>Am J Respir Cell Mol Biol</source> (<year>2022</year>) <volume>66</volume>(<issue>5</issue>):<page-range>510&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1165/rcmb.2021-0379OC</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Song</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Integrated analysis of the functions and clinical implications of exosome circRNAs in colorectal cancer</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>919014</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2022.919014</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nie</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>R</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gou</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA circFARSA promotes the tumorigenesis of non-small cell lung cancer by elevating B7H3 via sponging miR-15a-5p</article-title>. <source>Cell Cycle (Georgetown Tex)</source> (<year>2022</year>) <volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.1080/15384101.2022.2105087</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Exosomes derived from myeloid-derived suppressor cells facilitate castration-resistant prostate cancer progression <italic>via</italic> S100A9/circMID1/miR-506-3p/MID1</article-title>. <source>J Trans Med</source> (<year>2022</year>) <volume>20</volume>(<issue>1</issue>):<fpage>346</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-022-03494-5</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashwal-Fluss</surname> <given-names>R</given-names>
</name>
<name>
<surname>Meyer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Pamudurti</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Ivanov</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bartok</surname> <given-names>O</given-names>
</name>
<name>
<surname>Hanan</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>circRNA biogenesis competes with pre-mRNA splicing</article-title>. <source>Mol Cell</source> (<year>2014</year>) <volume>56</volume>(<issue>1</issue>):<fpage>55</fpage>&#x2013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2014.08.019</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Exon-intron circular RNAs regulate transcription in the nucleus</article-title>. <source>Nat Struct &amp;Molecular Biol</source> (<year>2015</year>) <volume>22</volume>:<page-range>256&#x2013;64</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nsmb.2959</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Legnini</surname> <given-names>I</given-names>
</name>
<name>
<surname>Di Timoteo</surname> <given-names>G</given-names>
</name>
<name>
<surname>Rossi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Morlando</surname> <given-names>M</given-names>
</name>
<name>
<surname>Briganti</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sthandier</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis</article-title>. <source>Mol Cell</source> (<year>2017</year>) <volume>66</volume>(<issue>1</issue>):<fpage>22</fpage>&#x2013;<lpage>37.e9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2017.02.017</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pamudurti</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Bartok</surname> <given-names>O</given-names>
</name>
<name>
<surname>Jens</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ashwal-Fluss</surname> <given-names>R</given-names>
</name>
<name>
<surname>Stottmeister</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ruhe</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Translation of CircRNAs</article-title>. <source>Mol Cell</source> (<year>2017</year>) <volume>66</volume>(<issue>1</issue>):<fpage>9</fpage>&#x2013;<lpage>21.e7</lpage>. doi:  <pub-id pub-id-type="doi">10.1016/j.molcel.2017.02.021</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>X</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Song</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Extensive translation of circular RNAs driven by N(6)-methyladenosine</article-title>. <source>Cell Res</source> (<year>2017</year>) <volume>27</volume>(<issue>5</issue>):<page-range>626&#x2013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1038/cr.2017.31</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>C</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Novel role of FBXW7 circular RNA in repressing glioma tumorigenesis</article-title>. <source>J Natl Cancer Institute</source> (<year>2018</year>) <volume>110</volume>(<issue>3</issue>):<page-range>304&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1093/jnci/djx166</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis</article-title>. <source>Oncogene</source> (<year>2018</year>) <volume>37</volume>(<issue>13</issue>):<page-range>1805&#x2013;14</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41388-017-0019-9</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>K</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<fpage>4475</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-018-02847-3</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abe</surname> <given-names>N</given-names>
</name>
<name>
<surname>Matsumoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nishihara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Nakano</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shibata</surname> <given-names>A</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Rolling circle translation of circular RNA in living human cells</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<fpage>16435</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep16435</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Patil</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zinoviev</surname> <given-names>A</given-names>
</name>
<name>
<surname>Skabkin</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Elemento</surname> <given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>5' UTR m(6)A promotes cap-independent translation</article-title>. <source>Cell</source> (<year>2015</year>) <volume>163</volume>(<issue>4</issue>):<fpage>999</fpage>&#x2013;<lpage>1010</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2015.10.012</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jaffrey</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Dynamic m(6)A mRNA methylation directs translational control of heat shock response</article-title>. <source>Nature</source> (<year>2015</year>) <volume>526</volume>(<issue>7574</issue>):<page-range>591&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature15377</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Sarnow</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs</article-title>. <source>Sci (New York NY)</source> (<year>1995</year>) <volume>268</volume>(<issue>5209</issue>):<page-range>415&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.7536344</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perriman</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ares</surname> <given-names>M</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Circular mRNA can direct translation of extremely long repeating-sequence proteins in vivo</article-title>. <source>RNA (New York NY)</source> (<year>1998</year>) <volume>4</volume>(<issue>9</issue>):<page-range>1047&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1017/S135583829898061X</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Efficient backsplicing produces translatable circular mRNAs</article-title>. <source>RNA (New York NY)</source> (<year>2015</year>) <volume>21</volume>(<issue>2</issue>):<page-range>172&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1261/rna.048272.114</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanahan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Weinberg</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>The hallmarks of cancer</article-title>. <source>Cell</source> (<year>2000</year>) <volume>100</volume>(<issue>1</issue>):<fpage>57</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubin Grandis</surname> <given-names>J</given-names>
</name>
<name>
<surname>Melhem</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Barnes</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Tweardy</surname> <given-names>DJ</given-names>
</name>
</person-group>. <article-title>Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck</article-title>. <source>Cancer</source> (<year>1996</year>) <volume>78</volume>(<issue>6</issue>):<page-range>1284&#x2013;92</page-range>. doi: <pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960915)78:6&lt;1284::AID-CNCR17&gt;3.0.CO;2-X</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell</article-title>. <source>J Hematol Oncol</source> (<year>2017</year>) <volume>10</volume>(<issue>1</issue>):<fpage>6</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-016-0376-9</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sooro</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy</article-title>. <source>Int J Cancer</source> (<year>2018</year>) <volume>143</volume>(<issue>9</issue>):<page-range>2116&#x2013;25</page-range>. doi: <pub-id pub-id-type="doi">10.1002/ijc.31398</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oliveira-Silva</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Carolina de Carvalho</surname> <given-names>A</given-names>
</name>
<name>
<surname>de Souza Viana</surname> <given-names>L</given-names>
</name>
<name>
<surname>Carvalho</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Reis</surname> <given-names>RM</given-names>
</name>
</person-group>. <article-title>Anti-EGFR therapy: Strategies in head and neck squamous cell carcinoma</article-title>. <source>Recent Patents Anti Cancer Drug Discov</source> (<year>2016</year>) <volume>11</volume>(<issue>2</issue>):<page-range>170&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.2174/1574892811666160309121238</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishola</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Chien</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>YP</given-names>
</name>
<name>
<surname>Chien</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yarmishyn</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Tsai</surname> <given-names>PH</given-names>
</name>
<etal/>
</person-group>. <article-title>Oncogenic circRNA C190 promotes non-small cell lung cancer <italic>via</italic> modulation of the EGFR/ERK pathway</article-title>. <source>Cancer Res</source> (<year>2022</year>) <volume>82</volume>(<issue>1</issue>):<fpage>75</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-1473</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname> <given-names>K</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7</article-title>. <source>Cell Death Dis</source> (<year>2018</year>) <volume>9</volume>(<issue>4</issue>):<fpage>417</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-018-0454-8</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA-encoded oncogenic e-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling</article-title>. <source>Nat Cell Biol</source> (<year>2021</year>) <volume>23</volume>(<issue>3</issue>):<page-range>278&#x2013;91</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41556-021-00639-4</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname> <given-names>YL</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>XQ</given-names>
</name>
</person-group>. <article-title>Circ-0079593 promotes proliferation and migration of melanoma cells by sponging microRNA-433 and elevating EGFR expression</article-title>. <source>Eur Rev Med Pharmacol Sci</source> (<year>2021</year>) <volume>25</volume>(<issue>2</issue>):<page-range>779&#x2013;86</page-range>. doi: <pub-id pub-id-type="doi">10.26355/eurrev_202101_24639</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway</article-title>. <source>BMC Cancer</source> (<year>2019</year>) <volume>19</volume>(<issue>1</issue>):<fpage>400</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12885-019-5593-5</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Bian</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Circular RNA ZNF609 promotes laryngeal squamous cell carcinoma progression by upregulating epidermal growth factor receptor <italic>via</italic> sponging microRNA-134-5p</article-title>. <source>Bioengineered</source> (<year>2022</year>) <volume>13</volume>(<issue>3</issue>):<page-range>6929&#x2013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21655979.2022.2034703</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robaina</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Mazzoccoli</surname> <given-names>L</given-names>
</name>
<name>
<surname>Klumb</surname> <given-names>CE</given-names>
</name>
</person-group>. <article-title>Germinal centre b cell functions and lymphomagenesis: Circuits involving MYC and MicroRNAs</article-title>. <source>Cells</source> (<year>2019</year>) <volume>8</volume>(<issue>11</issue>):<fpage>1365</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells8111365</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Song</surname> <given-names>W</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>C-myc-induced circ-NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the miR-34c-5p/c-Myc axis</article-title>. <source>Cell Biol Int</source> (<year>2021</year>) <volume>45</volume>(<issue>7</issue>):<page-range>1436&#x2013;47</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cbin.11582</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Splicing factor derived circular RNA circCAMSAP1 accelerates nasopharyngeal carcinoma tumorigenesis <italic>via</italic> a SERPINH1/c-myc positive feedback loop</article-title>. <source>Mol Cancer</source> (<year>2022</year>) <volume>21</volume>(<issue>1</issue>):<fpage>62</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-022-01502-2</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Splicing factor derived circular RNA circUHRF1 accelerates oral squamous cell carcinoma tumorigenesis <italic>via</italic> feedback loop</article-title>. <source>Cell Death Differ</source> (<year>2020</year>) <volume>27</volume>(<issue>3</issue>):<page-range>919&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41418-019-0423-5</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutschner</surname> <given-names>T</given-names>
</name>
<name>
<surname>Diederichs</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The hallmarks of cancer: a long non-coding RNA point of view</article-title>. <source>RNA Biol</source> (<year>2012</year>) <volume>9</volume>(<issue>6</issue>):<page-range>703&#x2013;19</page-range>. doi: <pub-id pub-id-type="doi">10.4161/rna.20481</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Neubauer</surname> <given-names>V</given-names>
</name>
<name>
<surname>Akagi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hanafusa</surname> <given-names>H</given-names>
</name>
<name>
<surname>Georgescu</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1</article-title>. <source>Mol Cell Biol</source> (<year>2003</year>) <volume>23</volume>(<issue>17</issue>):<page-range>6139&#x2013;49</page-range>. doi: <pub-id pub-id-type="doi">10.1128/MCB.23.17.6139-6149.2003</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worby</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Dixon</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>PTEN</article-title>. <source>Annu Rev Biochem</source> (<year>2014</year>) <volume>83</volume>:<page-range>641&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.1146/annurev-biochem-082411-113907</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>G</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Upregulation of circular RNA circATRNL1 to sensitize oral squamous cell carcinoma to irradiation</article-title>. <source>Mol Ther Nucleic Acids</source> (<year>2020</year>) <volume>19</volume>:<page-range>961&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2019.12.031</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Hsa_circ_0006232 promotes laryngeal squamous cell cancer progression through FUS-mediated EZH2 stabilization</article-title>. <source>Cell Cycle (Georgetown Tex)</source> (<year>2021</year>) <volume>20</volume>:<page-range>1799 &#x2013; 811</page-range>. doi: <pub-id pub-id-type="doi">10.1080/15384101.2021.1959973</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhai</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Circular RNA MYLK serves as an oncogene to promote cancer progression <italic>via</italic> microRNA-195/cyclin D1 axis in laryngeal squamous cell carcinoma</article-title>. <source>Biosci Rep</source> (<year>2019</year>) <volume>39</volume>(<issue>9</issue>):<fpage>BSR20190227</fpage>. doi: <pub-id pub-id-type="doi">10.1042/bsr20190227</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>B</given-names>
</name>
<name>
<surname>Tai</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>circRNA circ-CCND1 promotes the proliferation of laryngeal squamous cell carcinoma through elevating CCND1 expression <italic>via</italic> interacting with HuR and miR-646</article-title>. <source>J Cell Mol Med</source> (<year>2020</year>) <volume>24</volume>(<issue>4</issue>):<page-range>2423&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jcmm.14925</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>K</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Circ_0000745 strengthens the expression of CCND1 by functioning as miR-488 sponge and interacting with HuR binding protein to facilitate the development of oral squamous cell carcinoma</article-title>. <source>Cancer Cell Int</source> (<year>2021</year>) <volume>21</volume>(<issue>1</issue>):<fpage>271</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12935-021-01884-1</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramadan</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Shawkey</surname> <given-names>AE</given-names>
</name>
<name>
<surname>Rabeh</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Abdellatif</surname> <given-names>AO</given-names>
</name>
</person-group>. <article-title>Expression of P53, BAX, and BCL-2 in human malignant melanoma and squamous cell carcinoma cells after tea tree oil treatment in vitro</article-title>. <source>Cytotechnology</source> (<year>2019</year>) <volume>71</volume>(<issue>1</issue>):<page-range>461&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s10616-018-0287-4</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>YZ</given-names>
</name>
</person-group>. <article-title>The discovery of a novel inhibitor of apoptotic protease activating factor-1 (Apaf-1) for ischemic heart: synthesis, activity and target identification</article-title>. <source>Sci Rep</source> (<year>2016</year>) <volume>6</volume>:<fpage>29820</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep29820</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Kato</surname> <given-names>TA</given-names>
</name>
<name>
<surname>Hall</surname> <given-names>RP</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-3 promotes genetic instability and carcinogenesis</article-title>. <source>Mol Cell</source> (<year>2015</year>) <volume>58</volume>(<issue>2</issue>):<page-range>284&#x2013;96</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2015.03.003</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Circular RNA hsa_circ_0055538 regulates the malignant biological behavior of oral squamous cell carcinoma through the p53/Bcl-2/caspase signaling pathway</article-title>. <source>J Trans Med</source> (<year>2019</year>) <volume>17</volume>(<issue>1</issue>):<fpage>76</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-019-1830-6</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Du</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Circ_0005320 promotes oral squamous cell carcinoma tumorigenesis by sponging microRNA-486-3p and microRNA-637</article-title>. <source>Bioengineered</source> (<year>2022</year>) <volume>13</volume>(<issue>1</issue>):<page-range>440&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21655979.2021.2009317</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Millet</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>YE</given-names>
</name>
</person-group>. <article-title>Roles of Smad3 in TGF-beta signaling during carcinogenesis</article-title>. <source>Crit Rev Eukaryotic Gene Expression</source> (<year>2007</year>) <volume>17</volume>(<issue>4</issue>):<page-range>281&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1615/CritRevEukarGeneExpr.v17.i4.30</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Geng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Circ_0000218 plays a carcinogenic role in laryngeal cancer through regulating microRNA-139-3p/Smad3 axis</article-title>. <source>Pathol Res Pract</source> (<year>2020</year>) <volume>216</volume>(<issue>9</issue>):<fpage>153103</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.prp.2020.153103</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname> <given-names>E</given-names>
</name>
</person-group>. <article-title>Deconvoluting the context-dependent role for autophagy in cancer</article-title>. <source>Nat Rev Cancer</source> (<year>2012</year>) <volume>12</volume>(<issue>6</issue>):<page-range>401&#x2013;10</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrc3262</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bahrami</surname> <given-names>A</given-names>
</name>
<name>
<surname>Khazaei</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hassanian</surname> <given-names>SM</given-names>
</name>
<name>
<surname>ShahidSales</surname> <given-names>S</given-names>
</name>
<name>
<surname>Joudi-Mashhad</surname> <given-names>M</given-names>
</name>
<name>
<surname>Maftouh</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the tumor microenvironment as a potential therapeutic approach in colorectal cancer: Rational and progress</article-title>. <source>J Cell Physiol</source> (<year>2018</year>) <volume>233</volume>(<issue>4</issue>):<page-range>2928&#x2013;36</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcp.26041</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Nrf2-miR-129-3p-mTOR axis controls an miRNA regulatory network involved in HDACi-induced autophagy</article-title>. <source>Mol Ther J Am Soc Gene Ther</source> (<year>2019</year>) <volume>27</volume>(<issue>5</issue>):<page-range>1039&#x2013;50</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.010</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Qin</surname> <given-names>G</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dang</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Lyn Kinase promotes the proliferation of malignant melanoma cells through inhibition of apoptosis and autophagy <italic>via</italic> the PI3K/Akt signaling pathway</article-title>. <source>J Cancer</source> (<year>2019</year>) <volume>10</volume>(<issue>5</issue>):<page-range>1197&#x2013;208</page-range>. doi: <pub-id pub-id-type="doi">10.7150/jca.28908</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>XH</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>YX</given-names>
</name>
<name>
<surname>He</surname> <given-names>ZX</given-names>
</name>
<etal/>
</person-group>. <article-title>Bardoxolone methyl (CDDO-me or RTA402) induces cell cycle arrest, apoptosis and autophagy <italic>via</italic> PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells</article-title>. <source>Am J Trans Res</source> (<year>2017</year>) <volume>9</volume>(<issue>10</issue>):<page-range>4652&#x2013;72</page-range>.</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname> <given-names>N</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Khoor</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Leitges</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Protein kinase c&#x3b9; and wnt/&#x3b2;-catenin signaling: Alternative pathways to Kras/Trp53-driven lung adenocarcinoma</article-title>. <source>Cancer Cell</source> (<year>2019</year>) <volume>36</volume>(<issue>2</issue>):<fpage>156</fpage>&#x2013;<lpage>67.e7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ccell.2019.07.002</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sarkar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Bristow</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Dey</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Perets</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ramirez-Cardenas</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>PRKCI promotes immune suppression in ovarian cancer</article-title>. <source>Genes Dev</source> (<year>2017</year>) <volume>31</volume>(<issue>11</issue>):<page-range>1109&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1101/gad.296640.117</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kikuchi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Soundararajan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zarzabal</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Weems</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Nelon</surname> <given-names>LD</given-names>
</name>
<name>
<surname>Hampton</surname> <given-names>ST</given-names>
</name>
<etal/>
</person-group>. <article-title>Protein kinase c iota as a therapeutic target in alveolar rhabdomyosarcoma</article-title>. <source>Oncogene</source> (<year>2013</year>) <volume>32</volume>(<issue>3</issue>):<page-range>286&#x2013;95</page-range>. doi: <pub-id pub-id-type="doi">10.1038/onc.2012.46</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hongdu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>PRKCI negatively regulates autophagy <italic>via</italic> PIK3CA/AKT-MTOR signaling</article-title>. <source>Biochem Biophys Res Commun</source> (<year>2016</year>) <volume>470</volume>(<issue>2</issue>):<page-range>306&#x2013;12</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2016.01.059</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>H</given-names>
</name>
<name>
<surname>Niu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>166</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-020-01279-2</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname> <given-names>L</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Overexpression of circCDR1as drives oral squamous cell carcinoma progression</article-title>. <source>Oral Dis</source> (<year>2021</year>) <volume>00</volume>:<page-range>1&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1111/odi.14085</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Settembre</surname> <given-names>C</given-names>
</name>
<name>
<surname>Di Malta</surname> <given-names>C</given-names>
</name>
<name>
<surname>Polito</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Garcia Arencibia</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vetrini</surname> <given-names>F</given-names>
</name>
<name>
<surname>Erdin</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>TFEB links autophagy to lysosomal biogenesis</article-title>. <source>Sci (New York NY)</source> (<year>2011</year>) <volume>332</volume>(<issue>6036</issue>):<page-range>1429&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1204592</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dou</surname> <given-names>ZC</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>WH</given-names>
</name>
<name>
<surname>Li</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhi</surname> <given-names>KQ</given-names>
</name>
</person-group>. <article-title>CircCDR1as upregulates autophagy under hypoxia to promote tumor cell survival <italic>via</italic> AKT/ERK(&#xbd;)/mTOR signaling pathways in oral squamous cell carcinomas</article-title>. <source>Cell Death Dis</source> (<year>2019</year>) <volume>10</volume>(<issue>10</issue>):<fpage>745</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-019-1971-9</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Claesson-Welsh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Welsh</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>VEGFA and tumour angiogenesis</article-title>. <source>J Internal Med</source> (<year>2013</year>) <volume>273</volume>(<issue>2</issue>):<page-range>114&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1111/joim.12019</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deron</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vermeersch</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mees</surname> <given-names>G</given-names>
</name>
<name>
<surname>Vangestel</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pauwels</surname> <given-names>P</given-names>
</name>
<name>
<surname>Van de Wiele</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Expression and prognostic value of glucose transporters and hexokinases in tonsil and mobile tongue squamous cell carcinoma</article-title>. <source>Histol Histopathol</source> (<year>2011</year>) <volume>26</volume>(<issue>9</issue>):<page-range>1165&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.14670/hh-26.1165</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname> <given-names>P</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>RK</given-names>
</name>
</person-group>. <article-title>Molecular mechanisms and clinical applications of angiogenesis</article-title>. <source>Nature</source> (<year>2011</year>) <volume>473</volume>(<issue>7347</issue>):<fpage>298</fpage>&#x2013;<lpage>307</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature10144</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname> <given-names>GL</given-names>
</name>
<name>
<surname>Ruvolo</surname> <given-names>PP</given-names>
</name>
</person-group>. <article-title>Introduction to tumor microenvironment regulation of cancer cell survival, metastasis, inflammation, and immune surveillance</article-title>. <source>Biochim Biophys Acta</source> (<year>2016</year>) <volume>1863</volume>(<issue>3</issue>):<page-range>379&#x2013;81</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.bbamcr.2015.12.015</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Expression profile of circular RNAs in oral squamous cell carcinoma</article-title>. <source>Front Oncol</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>533616</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2020.533616</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sporn</surname> <given-names>MB</given-names>
</name>
</person-group>. <article-title>The war on cancer</article-title>. <source>Lancet (London England)</source> (<year>1996</year>) <volume>347</volume>(<issue>9012</issue>):<page-range>1377&#x2013;81</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(96)91015-6</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mittal</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Epithelial mesenchymal transition in tumor metastasis</article-title>. <source>Annu Rev Pathol</source> (<year>2018</year>) <volume>13</volume>:<fpage>395</fpage>&#x2013;<lpage>412</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-pathol-020117-043854</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yilmaz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Christofori</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>EMT, the cytoskeleton, and cancer cell invasion</article-title>. <source>Cancer Metastasis Rev</source> (<year>2009</year>) <volume>28</volume>(<issue>1-2</issue>):<fpage>15</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10555-008-9169-0</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polyak</surname> <given-names>K</given-names>
</name>
<name>
<surname>Weinberg</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits</article-title>. <source>Nat Rev Cancer</source> (<year>2009</year>) <volume>9</volume>(<issue>4</issue>):<page-range>265&#x2013;73</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrc2620</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Shuai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Knockdown of EBV-encoded circRNA circRPMS1 suppresses nasopharyngeal carcinoma cell proliferation and metastasis through sponging multiple miRNAs</article-title>. <source>Cancer Manage Res</source> (<year>2019</year>) <volume>11</volume>:<page-range>8023&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.2147/CMAR.S218967</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>N</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF <italic>via</italic> EMT and the PI3K/Akt/mTOR pathway</article-title>. <source>Cell Death Dis</source> (<year>2020</year>) <volume>11</volume>(<issue>8</issue>):<fpage>682</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-020-02851-w</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>F</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA circCORO1C promotes laryngeal squamous cell carcinoma progression by modulating the let-7c-5p/PBX3 axis</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>99</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-020-01215-4</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>33</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-020-01149-x</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname> <given-names>QS</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>YN</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>WB</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>QH</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>circRNA_0000140 suppresses oral squamous cell carcinoma growth and metastasis by targeting miR-31 to inhibit hippo signaling pathway</article-title>. <source>Cell Death Dis</source> (<year>2020</year>) <volume>11</volume>(<issue>2</issue>):<fpage>112</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-020-2273-y</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xf6;ttgens</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Span</surname> <given-names>PN</given-names>
</name>
<name>
<surname>Zegers</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>Roles and regulation of epithelial splicing regulatory proteins 1 and 2 in epithelial-mesenchymal transition</article-title>. <source>Int Rev Cell Mol Biol</source> (<year>2016</year>) <volume>327</volume>:<page-range>163&#x2013;94</page-range>. doi: <pub-id pub-id-type="doi">10.1016/bs.ircmb.2016.06.003</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matos</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Lapyckyj</surname> <given-names>L</given-names>
</name>
<name>
<surname>Rosso</surname> <given-names>M</given-names>
</name>
<name>
<surname>Besso</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Mencucci</surname> <given-names>MV</given-names>
</name>
<name>
<surname>Briggiler</surname> <given-names>CI</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a novel human e-cadherin splice variant and assessment of its effects upon EMT-related events</article-title>. <source>J Cell Physiol</source> (<year>2017</year>) <volume>232</volume>(<issue>6</issue>):<page-range>1368&#x2013;86</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcp.25622</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lekva</surname> <given-names>T</given-names>
</name>
<name>
<surname>Berg</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Lyle</surname> <given-names>R</given-names>
</name>
<name>
<surname>Heck</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ringstad</surname> <given-names>G</given-names>
</name>
<name>
<surname>Olstad</surname> <given-names>OK</given-names>
</name>
<etal/>
</person-group>. <article-title>Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas</article-title>. <source>Endocrinology</source> (<year>2013</year>) <volume>154</volume>(<issue>9</issue>):<page-range>3331&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1210/en.2013-1051</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warzecha</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Amirikian</surname> <given-names>K</given-names>
</name>
<name>
<surname>Dittmar</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition</article-title>. <source>EMBO J</source> (<year>2010</year>) <volume>29</volume>(<issue>19</issue>):<page-range>3286&#x2013;300</page-range>. doi: <pub-id pub-id-type="doi">10.1038/emboj.2010.195</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Atkinson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies</article-title>. <source>Cancer Lett</source> (<year>2017</year>) <volume>396</volume>:<page-range>103&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2017.03.008</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalerba</surname> <given-names>P</given-names>
</name>
<name>
<surname>Clarke</surname> <given-names>MF</given-names>
</name>
</person-group>. <article-title>Cancer stem cells and tumor metastasis: first steps into uncharted territory</article-title>. <source>Cell Stem Cell</source> (<year>2007</year>) <volume>1</volume>(<issue>3</issue>):<page-range>241&#x2013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.stem.2007.08.012</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Long non-coding RNAs in esophageal cancer: molecular mechanisms, functions, and potential applications</article-title>. <source>J Hematol Oncol</source> (<year>2018</year>) <volume>11</volume>(<issue>1</issue>):<fpage>118</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13045-018-0663-8</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Li</surname> <given-names>F</given-names>
</name>
<name>
<surname>Bo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines</article-title>. <source>J Cancer</source> (<year>2017</year>) <volume>8</volume>(<issue>3</issue>):<fpage>497</fpage>&#x2013;<lpage>506</lpage>. doi: <pub-id pub-id-type="doi">10.7150/jca.17444</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Niu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Whole-transcriptome analysis of CD133+CD144+ cancer stem cells derived from human laryngeal squamous cell carcinoma cells</article-title>. <source>Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol</source> (<year>2018</year>) <volume>47</volume>(<issue>4</issue>):<page-range>1696&#x2013;710</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000490992</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Talati</surname> <given-names>PG</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ellsworth</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Girondo</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Trerotola</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hoang</surname> <given-names>DT</given-names>
</name>
<etal/>
</person-group>. <article-title>Jak2-Stat5a/b signaling induces epithelial-to-Mesenchymal transition and stem-like cell properties in prostate cancer</article-title>. <source>Am J Pathol</source> (<year>2015</year>) <volume>185</volume>(<issue>9</issue>):<page-range>2505&#x2013;22</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.04.026</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Oh</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Do</surname> <given-names>SI</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Rho</surname> <given-names>YS</given-names>
</name>
<etal/>
</person-group>. <article-title>SOX2 regulates self-renewal and tumorigenicity of stem-like cells of head and neck squamous cell carcinoma</article-title>. <source>Br J Cancer</source> (<year>2014</year>) <volume>111</volume>(<issue>11</issue>):<page-range>2122&#x2013;30</page-range>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2014.528</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>CY</given-names>
</name>
</person-group>. <article-title>circFAT1 promotes cancer stemness and immune evasion by promoting STAT3 activation</article-title>. <source>Adv Sci (Weinheim Baden Wurttemberg Germany)</source> (<year>2021</year>) <volume>8</volume>(<issue>13</issue>):<fpage>2003376</fpage>. doi: <pub-id pub-id-type="doi">10.1002/advs.202003376</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massagu&#xe9;</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>TGFbeta in cancer</article-title>. <source>Cell</source> (<year>2008</year>) <volume>134</volume>(<issue>2</issue>):<page-range>215&#x2013;30</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2008.07.001</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sui</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>ZZ</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells</article-title>. <source>J Int Med Res</source> (<year>2012</year>) <volume>40</volume>(<issue>2</issue>):<page-range>426&#x2013;35</page-range>. doi: <pub-id pub-id-type="doi">10.1177/147323001204000204</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruhn</surname> <given-names>O</given-names>
</name>
<name>
<surname>Cascorbi</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance</article-title>. <source>Expert Opin Drug Metab Toxicol</source> (<year>2014</year>) <volume>10</volume>(<issue>10</issue>):<page-range>1337&#x2013;54</page-range>. doi: <pub-id pub-id-type="doi">10.1517/17425255.2014.952630</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ji</surname> <given-names>N</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>ZN</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JQ</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells</article-title>. <source>Cancer Lett</source> (<year>2019</year>) <volume>440&#x2013;441</volume>:<page-range>82&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.canlet.2018.10.007</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Circ_0109291 promotes the cisplatin resistance of oral squamous cell carcinoma by sponging miR-188-3p to increase ABCB1 expression</article-title>. <source>Cancer Biother Radiopharmaceuticals</source> (<year>2020</year>)  <volume>37</volume>(<issue>4</issue>):<page-range>233&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1089/cbr.2020.3928</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kostenko</surname> <given-names>S</given-names>
</name>
<name>
<surname>Moens</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology</article-title>. <source>Cell Mol Life Sci CMLS</source> (<year>2009</year>) <volume>66</volume>(<issue>20</issue>):<page-range>3289&#x2013;307</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00018-009-0086-3</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benjamin</surname> <given-names>IJ</given-names>
</name>
<name>
<surname>McMillan</surname> <given-names>DR</given-names>
</name>
</person-group>. <article-title>Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease</article-title>. <source>Circ Res</source> (<year>1998</year>) <volume>83</volume>(<issue>2</issue>):<page-range>117&#x2013;32</page-range>. doi: <pub-id pub-id-type="doi">10.1161/01.RES.83.2.117</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambert</surname> <given-names>H</given-names>
</name>
<name>
<surname>Charette</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Bernier</surname> <given-names>AF</given-names>
</name>
<name>
<surname>Guimond</surname> <given-names>A</given-names>
</name>
<name>
<surname>Landry</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus</article-title>. <source>J Biol Chem</source> (<year>1999</year>) <volume>274</volume>(<issue>14</issue>):<page-range>9378&#x2013;85</page-range>. doi: <pub-id pub-id-type="doi">10.1074/jbc.274.14.9378</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>HSP27-mediated extracellular and intracellular signaling pathways synergistically confer chemoresistance in squamous cell carcinoma of tongue</article-title>. <source>Clin Cancer Res an Off J Am Assoc Cancer Res</source> (<year>2018</year>) <volume>24</volume>(<issue>5</issue>):<page-range>1163&#x2013;75</page-range>. doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2619</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>IK</given-names>
</name>
<etal/>
</person-group>. <article-title>Overexpression of human 27 kDa heat shock protein in laryngeal cancer cells confers chemoresistance associated with cell growth delay</article-title>. <source>J Cancer Res Clin Oncol</source> (<year>2007</year>) <volume>133</volume>(<issue>1</issue>):<fpage>37</fpage>&#x2013;<lpage>46</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00432-006-0143-3</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>D</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Rui</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel intronic circular RNA, circGNG7, inhibits head and neck squamous cell carcinoma progression by blocking the phosphorylation of heat shock protein 27 at Ser78 and Ser82</article-title>. <source>Cancer Commun (London England)</source> (<year>2021</year>) <volume>41</volume>(<issue>11</issue>):<page-range>1152&#x2013;72</page-range>. doi: <pub-id pub-id-type="doi">10.1002/cac2.12213</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhi</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Circ-PKD2 promotes Atg13-mediated autophagy by inhibiting miR-646 to increase the sensitivity of cisplatin in oral squamous cell carcinomas</article-title>. <source>Cell Death Dis</source> (<year>2022</year>) <volume>13</volume>(<issue>2</issue>):<fpage>192</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-021-04497-8</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway</article-title>. <source>Cell Death Dis</source> (<year>2021</year>) <volume>12</volume>(<issue>4</issue>):<fpage>298</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-021-03558-2</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Overexpressed CDR1as functions as an oncogene to promote the tumor progression <italic>via</italic> miR-7 in non-small-cell lung cancer</article-title>. <source>OncoTargets Ther</source> (<year>2018</year>) <volume>11</volume>:<page-range>3979&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.2147/OTT.S158316</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butte</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Keir</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Phamduy</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Sharpe</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Freeman</surname> <given-names>GJ</given-names>
</name>
</person-group>. <article-title>Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</article-title>. <source>Immunity</source> (<year>2007</year>) <volume>27</volume>(<issue>1</issue>):<page-range>111&#x2013;22</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2007.05.016</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Omiya</surname> <given-names>R</given-names>
</name>
<name>
<surname>Matsumura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sakoda</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kuramasu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Augustine</surname> <given-names>MM</given-names>
</name>
<etal/>
</person-group>. <article-title>B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance</article-title>. <source>Blood</source> (<year>2010</year>) <volume>116</volume>(<issue>8</issue>):<page-range>1291&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1182/blood-2010-01-265975</pub-id>
</citation>
</ref>
<ref id="B139">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape</article-title>. <source>Mol Cancer</source> (<year>2019</year>) <volume>18</volume>(<issue>1</issue>):<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-018-0928-4</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>X</given-names>
</name>
<name>
<surname>He</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>19</fpage>. doi: 10.1186s12943-020-1144-6
</citation>
</ref>
<ref id="B141">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>BBY</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>WT</given-names>
</name>
<name>
<surname>Goh</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Hui</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Pettinger</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo clinic phase 2 consortium (NCI-9742)</article-title>. <source>J Clin Oncol Off J Am Soc Clin Oncol</source> (<year>2018</year>) <volume>36</volume>(<issue>14</issue>):<page-range>1412&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2017.77.0388</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mezzadra</surname> <given-names>R</given-names>
</name>
<name>
<surname>Schumacher</surname> <given-names>TN</given-names>
</name>
</person-group>. <article-title>Regulation and function of the PD-L1 checkpoint</article-title>. <source>Immunity</source> (<year>2018</year>) <volume>48</volume>(<issue>3</issue>):<page-range>434&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.014</pub-id>
</citation>
</ref>
<ref id="B143">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy</article-title>. <source>Sci China Life Sci</source> (<year>2021</year>) <volume>64</volume>(<issue>4</issue>):<page-range>534&#x2013;47</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11427-019-1735-4</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance</article-title>. <source>Cell Mol Life Sci CMLS</source> (<year>2021</year>) <volume>78</volume>(<issue>1</issue>):<page-range>173&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00018-020-03581-0</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lian</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Competing endogenous RNA network analysis of CD274, IL&#x2212;10 and FOXP3 co&#x2212;expression in laryngeal squamous cell carcinoma</article-title>. <source>Mol Med Rep</source> (<year>2018</year>) <volume>17</volume>(<issue>3</issue>):<page-range>3859&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.3892/mmr.2017.8307</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paget</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The distribution of secondary growths in cancer of the breast</article-title>. <source>1889 Cancer Metastasis Rev</source> (<year>1989</year>) <volume>8</volume>(<issue>2</issue>):<fpage>98</fpage>&#x2013;<lpage>101</lpage>.</citation>
</ref>
<ref id="B147">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendoza</surname> <given-names>M</given-names>
</name>
<name>
<surname>Khanna</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Revisiting the seed and soil in cancer metastasis</article-title>. <source>Int J Biochem Cell Biol</source> (<year>2009</year>) <volume>41</volume>(<issue>7</issue>):<page-range>1452&#x2013;62</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.biocel.2009.01.015</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>CK</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>QM</given-names>
</name>
</person-group>. <article-title>Role of the tumor microenvironment in tumor progression and the clinical applications (Review)</article-title>. <source>Oncol Rep</source> (<year>2016</year>) <volume>35</volume>(<issue>5</issue>):<page-range>2499&#x2013;515</page-range>. doi: <pub-id pub-id-type="doi">10.3892/or.2016.4660</pub-id>
</citation>
</ref>
<ref id="B149">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Theocharis</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Skandalis</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Gialeli</surname> <given-names>C</given-names>
</name>
<name>
<surname>Karamanos</surname> <given-names>NK</given-names>
</name>
</person-group>. <article-title>Extracellular matrix structure</article-title>. <source>Adv Drug Delivery Rev</source> (<year>2016</year>) <volume>97</volume>:<fpage>4</fpage>&#x2013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.addr.2015.11.001</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Fingleton</surname> <given-names>B</given-names>
</name>
<name>
<surname>Rothenberg</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Matrisian</surname> <given-names>LM</given-names>
</name>
</person-group>. <article-title>Matrix metalloproteinases: biologic activity and clinical implications</article-title>. <source>J Clin Oncol Off J Am Soc Clin Oncol</source> (<year>2000</year>) <volume>18</volume>(<issue>5</issue>):<page-range>1135&#x2013;49</page-range>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2000.18.5.1135</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA 0000096 affects cell growth and migration in gastric cancer</article-title>. <source>Br J Cancer</source> (<year>2017</year>) <volume>116</volume>(<issue>5</issue>):<page-range>626&#x2013;33</page-range>. doi: <pub-id pub-id-type="doi">10.1038/bjc.2016.451</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>CircLMNB1 promotes colorectal cancer by regulating cell proliferation, apoptosis and epithelial-mesenchymal transition</article-title>. <source>OncoTargets Ther</source> (<year>2019</year>) <volume>12</volume>:<page-range>6349&#x2013;59</page-range>. doi: <pub-id pub-id-type="doi">10.2147/OTT.S204741</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ren</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>He</surname> <given-names>L</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Knockdown of circDENND4C inhibits glycolysis, migration and invasion by up-regulating miR-200b/c in breast cancer under hypoxia</article-title>. <source>J Exp Clin Cancer Res CR</source> (<year>2019</year>) <volume>38</volume>(<issue>1</issue>):<fpage>388</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13046-019-1398-2</pub-id>
</citation>
</ref>
<ref id="B154">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinshaw</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Shevde</surname> <given-names>LA</given-names>
</name>
</person-group>. <article-title>The tumor microenvironment innately modulates cancer progression</article-title>. <source>Cancer Res</source> (<year>2019</year>) <volume>79</volume>(<issue>18</issue>):<page-range>4557&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>SMY</given-names>
</name>
<name>
<surname>Krinsky</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Woolaver</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>Tumor immune microenvironment in head and neck cancers</article-title>. <source>Mol Carcinog</source> (<year>2020</year>) <volume>59</volume>(<issue>7</issue>):<page-range>766&#x2013;74</page-range>. doi: <pub-id pub-id-type="doi">10.1002/mc.23162</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Shuai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Circular RNAs in the tumour microenvironment</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>8</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-019-1113-0</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rong</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>CircZDBF2 up-regulates RNF145 by ceRNA model and recruits CEBPB to accelerate oral squamous cell carcinoma progression <italic>via</italic> NF&#x3ba;B signaling pathway</article-title>. <source>J Trans Med</source> (<year>2022</year>) <volume>20</volume>(<issue>1</issue>):<fpage>148</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-022-03347-1</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Overexpression of circRNA_100290 promotes the progression of laryngeal squamous cell carcinoma through the miR-136-5p/RAP2C axis</article-title>. <source>Biomed Pharmacother = Biomed Parmacother</source> (<year>2020</year>) <volume>125</volume>:<fpage>109874</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2020.109874</pub-id>
</citation>
</ref>
<ref id="B159">
<label>159</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Circ_0008068 facilitates the oral squamous cell carcinoma development by microRNA-153-3p/acylgycerol kinase (AGK) axis</article-title>. <source>Bioengineered</source> (<year>2022</year>) <volume>13</volume>(<issue>5</issue>):<page-range>13055&#x2013;69</page-range>. doi: <pub-id pub-id-type="doi">10.1080/21655979.2022.2074106</pub-id>
</citation>
</ref>
<ref id="B160">
<label>160</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>WR</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Qiao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>RNA-Seq profiling of circular RNA in human lung adenocarcinoma and squamous cell carcinoma</article-title>. <source>Mol Cancer</source> (<year>2019</year>) <volume>18</volume>(<issue>1</issue>):<fpage>134</fpage>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.TARG-19-LB-A13</pub-id>
</citation>
</ref>
<ref id="B161">
<label>161</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nair</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Niu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Thompson</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kocher</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNAs and their associations with breast cancer subtypes</article-title>. <source>Oncotarget</source> (<year>2016</year>) <volume>7</volume>(<issue>49</issue>):<page-range>80967&#x2013;79</page-range>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.13134</pub-id>
</citation>
</ref>
<ref id="B162">
<label>162</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname> <given-names>KF</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>TY</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>YP</given-names>
</name>
<name>
<surname>Chien</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of plasma hsa_circ_0000190 and 0001649 as biomarkers for predicting the recurrence and treatment response of patients with oral squamous cell carcinoma</article-title>. <source>J Chin Med Assoc JCMA.</source> (<year>2022</year>) <volume>85</volume>(<issue>4</issue>):<page-range>431&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1097/JCMA.0000000000000700</pub-id>
</citation>
</ref>
<ref id="B163">
<label>163</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Preu&#xdf;er</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hung</surname> <given-names>LH</given-names>
</name>
<name>
<surname>Schneider</surname> <given-names>T</given-names>
</name>
<name>
<surname>Schreiner</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hardt</surname> <given-names>M</given-names>
</name>
<name>
<surname>Moebus</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Selective release of circRNAs in platelet-derived extracellular vesicles</article-title>. <source>J Extracell Vesicles</source> (<year>2018</year>) <volume>7</volume>(<issue>1</issue>):<fpage>1424473</fpage>. doi: <pub-id pub-id-type="doi">10.1080/20013078.2018.1424473</pub-id>
</citation>
</ref>
<ref id="B164">
<label>164</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Bao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis</article-title>. <source>Cell Res</source> (<year>2015</year>) <volume>25</volume>(<issue>8</issue>):<page-range>981&#x2013;4</page-range>. doi: <pub-id pub-id-type="doi">10.1038/cr.2015.82</pub-id>
</citation>
</ref>
<ref id="B165">
<label>165</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnostic value of RNA for hepatocellular carcinoma: a network meta-analysis</article-title>. <source>Biomarkers Med</source> (<year>2021</year>) <volume>15</volume>(<issue>18</issue>):<page-range>1755&#x2013;67</page-range>. doi: <pub-id pub-id-type="doi">10.2217/bmm-2021-0327</pub-id>
</citation>
</ref>
<ref id="B166">
<label>166</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA MTCL1 promotes advanced laryngeal squamous cell carcinoma progression by inhibiting C1QBP ubiquitin degradation and mediating beta-catenin activation</article-title>. <source>Mol Cancer</source> (<year>2022</year>) <volume>21</volume>(<issue>1</issue>):<fpage>92</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-022-01570-4</pub-id>
</citation>
</ref>
<ref id="B167">
<label>167</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>XD</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Song</surname> <given-names>LN</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Circular RNA ABCB10 contributes to laryngeal squamous cell carcinoma (LSCC) progression by modulating the miR-588/CXCR4 axis</article-title>. <source>Aging</source> (<year>2021</year>) <volume>13</volume>(<issue>10</issue>):<page-range>14078&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.18632/aging.203025</pub-id>
</citation>
</ref>
<ref id="B168">
<label>168</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ling</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA hsa_circ_001783 regulates breast cancer progression <italic>via</italic> sponging miR-200c-3p</article-title>. <source>Cell Death Dis</source> (<year>2019</year>) <volume>10</volume>(<issue>2</issue>):<fpage>55</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-018-1287-1</pub-id>
</citation>
</ref>
<ref id="B169">
<label>169</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating wnt/&#x3b2;-catenin pathway</article-title>. <source>Cell Death Dis</source> (<year>2020</year>) <volume>11</volume>(<issue>12</issue>):<fpage>1065</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-020-03276-1</pub-id>
</citation>
</ref>
<ref id="B170">
<label>170</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Li</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis</article-title>. <source>Cancer Gene Ther</source> (<year>2021</year>) <volume>28</volume>(<issue>3-4</issue>):<page-range>279&#x2013;93</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41417-020-00218-z</pub-id>
</citation>
</ref>
<ref id="B171">
<label>171</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Circular RNA hsa_circ_0009172 suppresses gastric cancer by regulation of microRNA-485-3p-mediated NTRK3</article-title>. <source>Cancer Gene Ther</source> (<year>2021</year>) <volume>28</volume>(<issue>12</issue>):<page-range>1312&#x2013;24</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41417-020-00280-7</pub-id>
</citation>
</ref>
<ref id="B172">
<label>172</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavenniah</surname> <given-names>A</given-names>
</name>
<name>
<surname>Luu</surname> <given-names>TDA</given-names>
</name>
<name>
<surname>Li</surname> <given-names>YP</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>TB</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ackers-Johnson</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy</article-title>. <source>Mol Ther J Am Soc Gene Ther</source> (<year>2020</year>) <volume>28</volume>(<issue>6</issue>):<page-range>1506&#x2013;17</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.ymthe.2020.04.006</pub-id>
</citation>
</ref>
<ref id="B173">
<label>173</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>W</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma</article-title>. <source>Cancer Res</source> (<year>2018</year>) <volume>78</volume>(<issue>11</issue>):<page-range>2839&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2808</pub-id>
</citation>
</ref>
<ref id="B174">
<label>174</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>CircRNA-5692 inhibits the progression of hepatocellular carcinoma by sponging miR-328-5p to enhance DAB2IP expression</article-title>. <source>Cell Death Dis</source> (<year>2019</year>) <volume>10</volume>(<issue>12</issue>):<fpage>900</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-019-2089-9</pub-id>
</citation>
</ref>
<ref id="B175">
<label>175</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Abraham</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation</article-title>. <source>Mol Ther Nucleic Acids</source> (<year>2018</year>) <volume>13</volume>:<page-range>312&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2018.09.010</pub-id>
</citation>
</ref>
<ref id="B176">
<label>176</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname> <given-names>S</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>CircPrimer 2.0: a software for annotating circRNAs and predicting translation potential of circRNAs</article-title>. <source>BMC Bioinf</source> (<year>2022</year>) <volume>23</volume>(<issue>1</issue>):<fpage>215</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12859-022-04705-y</pub-id>
</citation>
</ref>
<ref id="B177">
<label>177</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>CircPrimer: a software for annotating circRNAs and determining the specificity of circRNA primers</article-title>. <source>BMC Bioinf</source> (<year>2018</year>) <volume>19</volume>(<issue>1</issue>):<fpage>292</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12859-018-2304-1</pub-id>
</citation>
</ref>
<ref id="B178">
<label>178</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>CircZNF609 enhances hepatocellular carcinoma cell proliferation, metastasis, and stemness by activating the hedgehog pathway through the regulation of miR-15a-5p/15b-5p and GLI2 expressions</article-title>. <source>Cell Death Dis</source> (<year>2020</year>) <volume>11</volume>(<issue>5</issue>):<fpage>358</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-020-2441-0</pub-id>
</citation>
</ref>
<ref id="B179">
<label>179</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhong</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Leng</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>miR-449c-5p availability is antagonized by circ-NOTCH1 for MYC-induced NOTCH1 upregulation as well as tumor metastasis and stemness in gastric cancer</article-title>. <source>J Cell Biochem</source> (<year>2020</year>) <volume>121</volume>(<issue>10</issue>):<page-range>4052&#x2013;63</page-range>. doi: <pub-id pub-id-type="doi">10.1002/jcb.29575</pub-id>
</citation>
</ref>
<ref id="B180">
<label>180</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>circCAMSAP1 promotes osteosarcoma progression and metastasis by sponging miR-145-5p and regulating FLI1 expression</article-title>. <source>Mol Ther Nucleic Acids</source> (<year>2021</year>) <volume>23</volume>:<page-range>1120&#x2013;35</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.omtn.2020.12.013</pub-id>
</citation>
</ref>
<ref id="B181">
<label>181</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>PF</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>XY</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>XJ</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>GM</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma</article-title>. <source>Mol Cancer</source> (<year>2020</year>) <volume>19</volume>(<issue>1</issue>):<fpage>110</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-020-01222-5</pub-id>
</citation>
</ref>
<ref id="B182">
<label>182</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>ciRS-7 is a prognostic biomarker and potential gene therapy target for renal cell carcinoma</article-title>. <source>Mol Cancer</source> (<year>2021</year>) <volume>20</volume>(<issue>1</issue>):<fpage>142</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12943-021-01443-2</pub-id>
</citation>
</ref>
<ref id="B183">
<label>183</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>CiRS-7 functions as a ceRNA of RAF-1/PIK3CD to promote metastatic progression of oral squamous cell carcinoma <italic>via</italic> MAPK/AKT signaling pathways</article-title>. <source>Exp Cell Res</source> (<year>2020</year>) <volume>396</volume>(<issue>2</issue>):<fpage>112290</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yexcr.2020.112290</pub-id>
</citation>
</ref>
<ref id="B184">
<label>184</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gui</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Circular RNA MYLK promotes tumour growth and metastasis <italic>via</italic> modulating miR-513a-5p/VEGFC signalling in renal cell carcinoma</article-title>. <source>J Cell Mol Med</source> (<year>2020</year>) <volume>24</volume>(<issue>12</issue>):<page-range>6609&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jcmm.15308</pub-id>
</citation>
</ref>
<ref id="B185">
<label>185</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>X</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression</article-title>. <source>Theranostics</source> (<year>2018</year>) <volume>8</volume>(<issue>14</issue>):<page-range>4003&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.7150/thno.24106</pub-id>
</citation>
</ref>
<ref id="B186">
<label>186</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Circ_0109291 promotes cisplatin resistance of oral squamous cell carcinoma by sponging miR-188-3p to increase ABCB1 expression</article-title>. <source>Cancer Biother Radiopharmaceuticals</source> (<year>2022</year>) <volume>37</volume>(<issue>4</issue>):<page-range>233&#x2013;45</page-range>. doi: <pub-id pub-id-type="doi">10.1089/cbr.2020.3928</pub-id>
</citation>
</ref>
<ref id="B187">
<label>187</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ge</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>F</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Epstein-Barr Virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1</article-title>. <source>Cancer Res</source> (<year>2021</year>) <volume>81</volume>(<issue>19</issue>):<page-range>5074&#x2013;88</page-range>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.Can-20-4321</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>